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1 Introduction 
1.1 Proteins  
Proteins constitute most of the cell dry mass. When a cell is observed under a microscope 
or when its electrical or biochemical activity is analysed, we in essence observe proteins. 
They are not only the cellular building blocks, but they also execute nearly all cell 
functions. 
Proteins embedded in the plasma membrane form channels, transporters and pumps that 
control the passage of small molecules in und out of the cell. Other proteins carry 
messages from one cell to another or act as signal integrators that relay sets of signals 
inward from the plasma membrane to the cell nucleus, for example the family of 
serine/threonine kinases. 
 
1.1.1 Membrane proteins involved in solute transport 
The vast majority of solutes cross membranes with the help of membrane proteins. Special 
membrane transport proteins are responsible for transfering lipophobe solutes across cell 
membranes. These proteins occur in many forms and in all types of biological 
membranes. Each protein transports only a particular class of molecules such as ion, 
sugars or aminoacids and often their transport characteristics are very specific and 
restricted to few members of each class. 
Transporters and channels are the two major classes of membrane transport proteins. 
Tranporters bind the specific solute and undergo a series of conformational changes to 
transfer the bound solute accros the membrane. Channel proteins in contrast, do not 
interact with the transported solute. All channels and many transporters allow solutes to 
cross the membrane only passively – a process called passive transport. In the case of 
transport of a single uncharged molecule, it is simply the difference of its concentration on 
the two sides of the membrane – its concentration gradient – that drives passive transport 
and determines its direction. If the solute carries a net charge however, both its 
concentration gradient and the electrical potential difference across the membrane, 
influence its transport. Cells require transport proteins that will actively pump certain 
solutes across the membrane against their electrochemical gradient; this process, known as 
active transport, is mediated by pumps. Thus, transport by carriers can be either active or 
passive, whereas transport by channel proteins is always passive. 
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One of the best understood pumps is the Na+/K+ ATPase. The sodium-potassium pump is 
probably the single most important transport protein in animal cells because it maintains 
the concentration gradient of Na+ and K+ across the cell membrane. The transporter is 
situated on the basolateral side of the cell membrane and pumps 3Na+out of the cell and 
2K+ into the cell for each ATP consumed. 
The energy for the active transport comes either directly or indirectly from the high-
energy phosphate bond of ATP. 
 
1.2 Protein Kinases 
A protein kinase is an enzyme that modifies other proteins by chemically adding 
phosphate groups to them a process called phosphorylation. Phosphorylation usually 
results in a functional change of the target protein (substrate) by changing enzyme 
activity, cellular location, or association with other proteins. 
Protein phosphorylation involves the enzyme – catalyzed transfer of the terminal 
phosphate group of an ATP molecule to the hydroxyl group of a serine or threonine side 
chain of a protein  This reaction is catalyzed by a protein kinase, and the reaction is 
essentially unidirectional because of the large amount of free energy released when the 
phosphate –phosphate bond in ATP is broken to produce ADP. 
The different protein kinases in a eucaryotic cell are organized into complex networks of 
signalling pathways which help to coordinate cell activites, drive the cell cycle, and relay 
signals into the cell from their environment  
Serine/threonine protein kinases phosphorylate the OH- group of serine or threonine 
(which have similar sidechains). The activity of these protein kinases can be regulated by 
specific events (e.g. DNA damage), as well as numerous chemical signals, including e.g. 
cAMP/cGMP. 
 
1.2.1 Phosphoinositide 3-kinases - PI3-Kinase 
The PI3- kinase enzymes are a group of ubiquitously expressed proteins that were shown 
to be essential for a plethora of biological responses including cell survival, cell 
proliferation, glucose and aminoacids transport, actin polymerisation and membrane 
ruffling.  
The PI3 kinase family of enzymes is recruited upon growth factor receptor activation and 
produces 3' phosphoinositide lipids. The lipid products of PI3K act as second messengers 
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by binding to and activating diverse cellular target proteins. These events constitute the 
start of a complex signaling cascade, which ultimately results in the mediation of cellular 
activities such as proliferation, differentiation, chemotaxis, survival, trafficking, or 
glucose homeostasis. Therefore, PI3Ks play a central role in many cellular functions. The 
factors that determine which cellular function is mediated are complex and may be partly 
attributed to the diversity that exists at each level of the PI3K signaling cascade, such as 
the type of stimulus, the isoform of PI3K, or the nature of the second messenger lipids. 
Numerous studies have helped to elucidate some of the key factors that determine cell fate 
in the context of PI3K signaling. Transgenic and knockout mouse studies where either 
PI3K or its signaling components are modified have helped to build a picture of the role of 
PI3K in physiology and indeed there have been a number of surprises.  
Phosphoinositide 3-kinases generate specific inositol lipids that have been implicated in 
the regulation of cell growth, proliferation, survival, differentiation and cytoskeletal 
changes. One of the best characterized targets of PI3K lipid products is the protein kinase 
Akt or protein kinase B (PKB). In quiescent cells, PKB resides in the cytosol in a low-
activity conformation. Upon cellular stimulation, PKB is activated through recruitment to 
cellular membranes by PI3K lipid produc ts and phosphorylation by PDK1 (1). 
Upon phosphorylation of PI3,4,5-P3 by PI3-kinase, the PH-containing phosphoinositide 
depedent protein kinase (PDK)-1 and 2 are recruited to the plasma membrane. 
Translocation to the membrane coincides with their activation, respectively. Interestingly, 
PDK1 has been described as a governing point for the activation of a number of different 
other kinases such as Akt/PKB, SGK isoforms and PKC?.  
 
1.2.2 SGKs belong to a family of serine/threonine kinases 
 Serum and glucocorticoid-inducible kinases (SGKs) belong to a family of 
serine/threonine kinases that are regulated at both the transcriptional and posttranslational 
levels by external stimuli. SGKs are members of the AGC subfamily that includes the 
PKC isoforms, cyclic-AMP-dependent PKA and p90RSK. There are 3 isoforms, SGK1, 
SGK2 and SGK3. The transcriptional regulation of the two closely related isoforms, 
SGK2 and SGK3, are not well understood. So far it is known tha t both can be activated by 
phosphorylation and that SGK3 has some role in the IL-3 mediated survival of 
hematopoietic cells. SGK1 contains a catalytic domain that is ~45-55% homologous to the 
catalytic domains of PKA, PKB, PKC-? and rat p70S6K/p85 S6K kinases which 
propagate cell signalling cascades associated with the control of cell growth, 
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differentiation and cell survival. The availability and function of SGK1 is regulated at 
three distinct levels of cellular control. First, SGK1 gene expression is strongly stimulated 
by hormonal and non hormonal stimuli. Second, like PKB, SGK1 is phosphorylated and 
enzymatically activated as a downstream component of the PI 3-kinase signalling cascade 
that mediates the mitogenic and cell survival responses to many growth factors and 
insulin. Finally, the subcellular localization of SGK1 is controlled by the cell cycle and 
exposure to specific hormones and environmental stress stimuli. SGK1 plays an important 
role in activating certain potassium, sodium and chloride channels, suggesting an 
involvement in the regulation of membrane transport (2-4). 
SGK1 is subject to complex regulatory mechanisms. Cross-talk among these signaling 
pathways may play an important role in the pathogenesis of  hypertension associated with 
hyperinsulinemia, obesity, and insulin resistance (5). 
 
1.2.3 SGK1 Regulation of Epithelial Sodium Transport 
Epithelial ion transport in vertebrates is regulated by a variety of hormonal and non-
hormonal factors, including mineralocorticoids, insulin, and osmotic differences. SGK1 
has been established as an important convergence point for multiple regulators of Na+ 
transport. Unlike most other serine-threonine kinases, SGK1 is under dual control: protein 
levels are controlled through effects on its gene transcription, while its activity is 
dependent on PI3 -Kinase. Aldosterone is the most known regulator of SGK1 protein level 
in ion transporting epithelia, while insulin and other activators of PI3K are key regulators 
of its activity. Activated SGK1 regulates a variety of ion transporters, the best 
characterized of which is the epithelial sodium channel (ENaC). The apical targeting of 
ENaC is controlled by the ubiquitin ligase Nedd4-2, and SGK1. SGK1 acts, at least in 
part, through phosphorylation-dependent inhibition of Nedd4-2. This effect of SGK1 
requires physical association of Nedd4-2 with both SGK1 and ENaC. Moreover, direct 
physical association between SGK1 and ENaC may also be implicated in the formation of 
a tertiary complex. Osmotic shock is likely the most important non-hormonal regulator of 
SGK1 expression, and surprisingly, SGK1 expression can be induced by hypotonic or 
hypertonic stress in a cell-type dependent fashion. The SGK family represents an ancient 
arm of the serine-threonine kinase family, present in all eukaryotes that have been 
examined, including yeast. SGK1 appears to have been implicated in membrane 
trafficking and possibly in the control of ion transport and cell volume in early single cell 
eukaryotes. In metazoan epithelia, it seems likely that SGK1 was adapted to the regulation 
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of ion transport in response to hormonal and osmotic signals (6). 
SGKs activate ion channels (e.g., ENaC, TRPV5, ROMK, Kv1.3, KCNE1/KCNQ1, 
GluR1, GluR6), carriers (e.g., NHE3, GLUT1, SGLT1, EAAT1-5), and the Na+-K+-
ATPase. They regulate the activity of enzymes (e.g., glycogen synthase kinase-3, 
ubiquitin ligase Nedd4-2, phosphomannose mutase-2) and transcription factors (e.g., 
forkhead transcription factor FKHRL1, beta-catenin, nuclear factor kappaB). SGKs 
participate in the regulation of transport, hormone release, neuroexcitability, cell 
proliferation, and apoptosis. SGK1 contributes to Na+ retention and K+ elimination of the 
kidney, mineralocorticoid stimulation of salt appetite, glucocorticoid stimulation of 
intestinal Na+/H+ exchanger and nutrient transport, insulin-dependent salt sensitivity of 
blood pressure and salt sensitivity of peripheral glucose uptake, memory consolidation, 
and cardiac repolarization. A common (prevalence approximately 5%) SGK1 gene variant 
is associated with increased blood pressure and body weight. SGK1 may thus contribute 
to the metabolic syndrome. SGK1 may further participate in tumor growth, 
neurodegeneration, fibrosing disease, and the sequelae of ischemia. SGK3 is required for 
adequate hair growth and maintenance of intestinal nutrient transport and influences 
locomotive behavior. In conclusion, the SGKs cover a wide variety of physiological 
functions and may play an active role in a multitude of pathophysiological conditions. 
There is little doubt that further targets will be identified that are modulated by the SGK 
isoforms and that further SGK-dependent physiological functions and pathophysiological 
conditions will be defined.(7) 
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Figure 1. Model for the Serum- and Glucocorticoid-inducible Kinase-1 (SGK1)-dependent regulation of Na+ 
reabsorption and K+ secretion in the aldosterone-sensitive distal nephron. Aldosterone binds to 
mineralocorticoid receptors (MR) and stimulates the expression of SGK1, a-epithelial Na+ channel (a  
ENaC), renal outer medullary K+ channel (ROMK), and the Na+-K+-ATPase. (7) 
 
1.3 Transepithelial transport 
All the transport processes described in the previous sections deal with the movement of 
molecules across a single membrane, that of the cell. Molecules cross the first membrane 
when they move into an epithelial cell from the external enviroment and cross the second 
when they leave the epithelial cell to enter the extracellular fluid. Movement across 
epithelial cells, transepithelial transport, uses a combination of active and passive 
transport mechanisms. The transporting epithelium of the intestine is specialized to 
selectively transport molecules into and out of the body. The surface of the epithelial cell 
that faces the lumen of an organ is called the apical membrane. It is often folded into 
microvilli that increase its surface area. Transporting epithelial cells are said to be 
polarized because their apical and basolateral membranes have different properties. 
Certain transport proteins such as the Na+-K+-ATPase, are almost (always) found only on 
the basolaterale membrane, whereas other like the Na+ - glucose symporter are localized 
to the apical membrane. 
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Figure 2: Glucose transport in intestinal epithelial cells. 
The glucose/Na+ symport uses the energy stored in the Na+ gradient (produced by the Na+/K+ ATPase) to 
transport glucose against its concentration gradient.  
 
Glucose transport is of fundamental importance for energy metabolism. The maintenance 
of a relatively constant blood glucose concentration to sustain cerebral metabolism and the 
delivery of glucose to peripheral tissues for storage and utilization are key metabolic 
processes. In many situations, transport of glucose across cell membranes plays a key role 
in its regulation and control.(8). 
Glucose enters eucaryotic cells via 2 different types of membrane associated carrier 
proteins, the Na+-coupled glucose transporters (SGLT) and the glucose transporter 
facilitators (GLUT). Three members of the SGLT family function as sugar transporters 
(SGLT1 and SGLT2) or sensors (SGLT3). The human GLUT family consists of 14 
members, of which 11 have been shown to catalyze sugar transport (9). 
Intestinal and renal transport of glucose is accomplished by Na+-coupled uptake across 
the apical cell membrane. Little is known about the cellular mechanisms mediating the 
regulation of glucose transport. Recently, a novel mechanism of transport regulation was 
described for the renal epithelial Na+ channel ENaC. The ubiquitin ligase neuronal cell 
expressed evelopmentally downregulated neuronal cell expressed developmentally 
downregulated 4-2 (Nedd4-2) (10); ubiquitinates the channel protein, thereby inducing the 
subsequent clearance of the channel protein from the cell membrane (11;12). Nedd4-2 is 
phosphorylated and inactivated by the serum- and glucocorticoid-dependent kinase 1 
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(SGK1) (13).In vitro experiments have revealed the ability of SGK1 to stimulate intestinal 
Na+-coupled glucose cotransporter 1 (SGLT1) and intestinal Na+/H+ exchanger 3 (NHE3).  
1.3.1 PI3 kinase a regulator of intestinal nutrient transport 
According to in vitro coexpression studies in Xenopus oocytes, protein kinase B/Akt 
(11;12) and the SGK1(2), SGK2 (14) and SGK3 (14) Kinases upregulate a variety of 
channels and transporters, (4;15;16) including the electrogenic glucose transporter SGLT1 
(13), the glutamine transporter SN1 (17), and the glutamate transporters EAAT1 (17), 
EAAT2 (18), EAAT3 (19), EAAT4 (20)and EAAT5 (21).  
The PKB and SGK isoforms are activated through the PI3 - Kinase and PDK1 (3;22-27). 
Thus, PI3 kinase may be a regulator of intestinal nutrient transport. 
The present experiments have been performed to explore whether pharmacological 
inhibiton oder gene knock-out of serine/threonine kinases interferes with electrogenic 
glucose and/or amino acid transport. 
 
1.3.2 Impact of PDK1 on transport of amino acids in the intestine  
PKB and SGKs are activated by IGF1 and insulin through the PI3 - Kinase and PDK1 
(3;22-28). The PI3 kinase pathway is an integral element of growth factor, insulin and 
interferon signalling (29-33). Its pleotropic functions include the regulation of cell 
survival (34;35) and cell proliferation (36-39). Moreover, inactivation of PDK1 by the 
phosphatase PTEN is abrogated by oxidation and thus, PDK1 participates in the signaling 
of oxidative stress (40). In view of its influence on the PKB and SGK isoforms, PDK1 
may be a master switch in the growth factor, insulin and stress dependent regulation of 
amino acid transport. 
The PDK1-knockout-mouse is not viable (41), highlighting the functional importance of 
this kinase. Mice with suppressed PDK1 activity to of up to ~ 20 % (pdk1hm) are 
significantly smaller than their age and sex matched wild type littermates (pdk1wt) (41). 
The smaller weight of the animals appeared to be primarily due to decreased cell volumes 
and not cell number (41). Among the determinants of cell volume is the concentrative 
cellular uptake of amino acids (42-44). 
Several amino acid transport systems contribute to the intestinal absorption or renal 
proximal tubular reabsorption of amino acids in mammals (45-47). Neutral amino acids 
are mainly transported by the Na+-dependent system B0 and IMINO encoded by the 
B0AT1 (SLC6A19) and SIT (SLC6A20) (47-50). Accordingly, mutations in B0AT1 are 
I                                                                                                                            Introduction  
9 
responsible for Hartnup disease, characterized by the impaired transport of neutral amino 
acids in the intestine and renal proximal tubule (51;52), . Anionic amino acids are 
transported in a Na+- and K+-dependent manner by the system X-AG EAAC1/ EAAT3 
(SLC1A1) transporter, whereas cationic amino acids and cystine are transported by the 
dimeric b0, +AT/rBAT (SLC7A9/ SLC3A1) transporter. Mutations in either b0,+AT or 
rBAT cause cystinuria with reduced transport of these amino acids both in intestine and 
kidney, (46;53). Up to date, little to nothing is known about the regulation of these 
transport systems in vivo. 
 
1.3.3 SGK3 participates in epithelial transport regulation  
The serum and glucocorticoid inducible kinase SGK1 was originally cloned as a 
glucocorticoid inducible gene (2;54;55). Homology screening led to the discovery of the 
isoforms SGK2 and SGK3, (14;56) which appear not to be transcriptional targets of 
glucocorticoids or serum (4). SGK3 has independently been discovered as “cytokine 
independent survival kinase” CISK (31). All three kinases are activated by IGF1 and 
insulin through the phosphatidyl- inositol 3 (PI3) kinase and phosphoinositide-dependent 
kinase PDK1 (3;22-24;26-28). 
The ability of SGK3 to regulate transport mechanisms in heterologous expression systems 
raises the question whether SGK3 participates in epithelial transport regulation in vivo. As 
shown recently, gene targeted mice lacking functional SGK3 (sgk3-/-) gain weight after 
birth slightly slower than their wild type littermates (sgk3+/+) (57), which could point to 
some impairment of intestinal absorption. 
1.3.4 Transepithelial potential and amiloride-sensitive short circuit current 
SGK1 was originally cloned as a glucocorticoid inducible gene (2;55). It was 
subsequently shown to be upregulated by mineralocorticoids (58-60). The human SGK1 
was discovered as a cell volume-sensitive gene up-regulated by cell shrinkage (61). SGK1 
was shown to participate in the regulation of renal Na+ (58-60;62-64). and K+ (65) 
excretion. SGK1 transcription is up-regulated by mineralocorticoids (58-60).  
In Xenopus oocytes expressing the a, ß, ?-subunits of ENaC, coexpression of SGK1 
results in a marked up-regulation of Na+-channel activity (58;66-70). Similarly, SGK1 has 
been shown to stimulate ENaC activity in cortical collecting duct cells (71;72) and A6 
cells (73;74). 
Under regular salt intake, gene targeted mice lacking SGK1 (sgk1-/-) excrete similar 
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amounts of NaCl as their wild-type littermates (sgk1+/+) (64).Thus, lack of SGK1 does not 
lead to the severe phenotype of mice lacking functional aENaC (75;76), ßENaC (77), 
?ENaC (78) or the mineralocorticoid receptor (79). The defective regulation of renal Na+ 
excretion only becomes apparent following exposure to salt deficient diet which unmasks 
the limited ability of the (sgk1-/-) mice to decrease their urinary Na+ output (64). Perfusion 
of isolated collecting ducts disclosed that the impaired renal Na+ retention was paralleled 
by decreased transepithelial voltage and amiloride sensitive current in this nephron 
segment (61;64). 
At least in theory, the regulation of ENaC in colon may similarly involve SGK1. 
Conflicting data have been reported on the colonic regulation of SGK1 by 
mineralocorticoids. In one study, the abundance of SGK1 in the distal colon did not 
change significantly after sodium depletion or after a single dose of aldosterone (80). 
Other studies, however, reported that SGK1 mRNA levels (60;81;82) and protein levels 
(81) were significantly elevated in the distal colon in response to aldosterone.  
Hitherto, nothing is known about the functional role of SGK1 in colonic epithelium. 
 
1.3.5 Aims of the studies 
The aim of the present study was to assess the function and regulation of intestinal 
transport by different protien kinases using sensitive inhibitors of tubular function and 
epithelium transporters. Special emphasis was applied on PI3K sig., Pdk1, Sgk1, Sgk3. 
For that purpose experiments were carried out with following objectives: 
To elucidate the regulation of intestinal glucose and amino acid transport activity by the 
serum and glucocortikoid inducible kinase isoforms SGK1, SGK3, protein kinase B and 
other PI3-kinases. 
To identify the role of SGK3 in upregulation of a variety of transport systems including 
the sodium depedent glucose transporter SGLT1. 
To assess the Sgk1 mediated influence of mineralocorticoids on ENaC activity in the 
colon.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
Aida Image Analyzer software, Raytest,  Germany. 
Camera Proxitronic, Bensheim, Germany. 
Eppendorf Centrifuge 5415R Hinz GmbH, Hamburg, Germany. 
Eppendorf Pipets 1000µl, 200µl, 20µl, 10µl,Eppendorf, Hamburg, Germany. 
Flame photometry, AFM 5051, Eppendorf, Hamburg, Germany. 
Fluorescence microscope (Axiovert, Zeiss, Jena, Germany). 
Fluorescence Microscopy low lightCCD camera/NIR/UV, Proxitronic Bensheim 
Germany. 
Glucometer Accutrend, Roche, Mannheim, Germany 
Lambda 10-2 Sutter Instrument Company, Novato, USA. 
Lamp ebx 75 isolated Leika, Jena Germany. 
MagNa Lyser (Roche Diagnostics, Mannheim, Germany) 
Mastercycler gradient Eppendorf, Hamburg, Germany. 
Metabolic cages ,Tecniplast, Hohenpeissenberg, Germany. 
Microflow Biological Safety, Cabinet Nalge Nunc Wiesbaden-Bierbach Germany. 
Microscope Zeiss Axiovert 135, Oberkochen, Germany. 
Microscope Zeiss Stemi 2000, Oberkochen, Germany. 
Milli-Q, MILLIPORE S.A. Molsheim France. 
Na-Heparine disposable capillaries 
Petridishes ,Greiner Bio-one, Frickenhausen, Germany. 
pH Meter 646,Carl Zeiss, Oberkochen, Germany. 
Preparation material, F.S.T. Heildelberg, Germany. 
Vortex ,Labnet Abimed, Langenfeld, Germany.. 
 
2.1.2 Chemicals  
Amiloride      Sigma, Taufkirchen, Germany 
BaCl2x2H2O     Carl Roth, Karlsruhe, Germany. 
Buffer –formamide    Sigma, Taufkirchen, Germany. 
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BSA bovine serum albumine Sigma   Sigma, Taufkirchen, Germany. 
CaCl2x2H2O     Carl Roth, Karlsruhe, Germany. 
Ca-Gluconate     Sigma, Taufkirchen, Germany. 
Carbogen mixture 95% O2 and 5% CO2   Air Liquide Düsseldorf Germany. 
Deoxycorticosterone acetate DOCA  Sigma, Taufkirchen, Germany. 
Dextran sulfate    Sigma, Taufkirchen, Germany. 
Diethyl ether     Carl Roth, Karlsruhe, Germany. 
DOCA pellets ,50 mg,   Innovative Research of America, Sarasota, FL, USA. 
EDTA  Ethylenediamine tetraacetic acid  Sigma, Taufkirchen, Germany. 
Ethanol absolute (99%)   Sigma-Aldrich; Hannover, Germany. 
Forskolin      Sigma, Taufkirchen, Germany. 
Glucose     Carl Roth Karlsruhe Germany. 
HCl       Sigma, Taufkirchen, Germany. 
HEPES     Sigma, Taufkirchen, Germany. 
Indomethacin     Sigma, Taufkirchen, Germany. 
K gluconate     Sigma, Taufkirchen, Germany. 
K2HPO4x2H20    Sigma, Taufkirchen, Germany. 
Kaiser’s gelatine     Merck, Darmstadt, Germany.  
Kaiser’s solution     Merck, Darmstadt, Germany.  
KCl      Carl Roth Karlsruhe Germany. 
KH2PO4      Sigma, Taufkirchen, Germany. 
L-Alanin     Carl Roth, Karlsruhe, Germany. 
L-Arginin     Carl Roth, Karlsruhe, Germany. 
L-Cystein     Carl Roth, Karlsruhe, Germany. 
L-Glutamin     Carl Roth, Karlsruhe, Germany. 
L-Leucine     Carl Roth Karlsruhe, Germany. 
L-Lysine     Carl Roth Karlsruhe, Germany. 
L-Methionin     Carl Roth, Karlsruhe, Germany. 
L-Methionine     Carl Roth Karlsruhe, Germany. 
L-Phenylalanine    Carl Roth, Karlsruhe, Germany. 
L-Prolin     Carl Roth, Karlsruhe, Germany. 
L-Tryptophan     Carl Roth Karlsruhe, Germany. 
L-Valine     Carl Roth Karlsruhe, Germany. 
LY-294,002 Hydrochloride    Sigma, Taufkirchen, Germany. 
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Mannitol     Sigma, Taufkirchen, Germany. 
MgCl2 x 6H2O    Sigma, Taufkirchen, Germany. 
MgSO4     Sigma, Taufkirchen, Germany. 
Na - Pyruvat     Sigma, Taufkirchen, Germany. 
NaCl      Sigma, Taufkirchen, Germany. 
Na-lactate      Sigma, Taufkirchen, Germany. 
Nitric acid       Carl Roth, Karlsruhe, Germany. 
Nitroblue tetrazolium salt (NBT)  Sigma, Taufkirchen, Germany 
N-Methyl-d-glucamine (NMDG)  Sigma, Taufkirchen, Germany. 
Paraformaldehyde    Carl Roth, Karlsruhe, Germany. 
Phloridzin     Sigma, Taufkirchen, Germany. 
PFA- Paraformaldehyd    Merck, Darmstadt, Germany. 
Saline 0.9%      Fresenius Kabi Bad Homburg Germany. 
phosphate buffered DAPI (4'-6-Diamidino-2-phenylindole) Sigma, Taufkirchen, Germany 
Sodium bicarbonate    Sigma, Taufkirchen, Germany. 
Sterilium     Carl Roth, Karlsruhe, Germany. 
TEA buffer  triethanolamine acetic anhydride Sigma, Taufkirchen, Germany. 
Tris buffer,     Sigma, Taufkirchen, Germany. 
Wortmannin     Sigma, Taufkirchen, Germany.    
5-bromo-4-chloro-3-indolyl phosphate (X-phosphate), Sigma, Taufkirchen, Germany. 
  
2.1.3 Kits 
Aanti-DIG antibody     Roche, USA  
CDP Star kit      Roche, USA. 
Creatinine kit enzymatic colorimetric method, Lehmann, Berlin, Germany.   
Death Detection Kit   Roche Applied Sciences, Mannheim, Germany. 
Detection Kit     Roche Applied Sciences, Mannheim, Germany. 
DIG nucleic acid detection kit  Roche, Basel Schwitzerland. 
DIG-labeling kit   Roche, Molecular Biochemicals, Mannheim, 
Germany. 
ELISA kit      dsl, Webster, USA. 
Glucose kit: gluco-quant®,   Roche Diagnostics, Mannheim, Germany. 
GoTaq® Green Master Mix    Promega, Madison, USA. 
PTH Elisa kit,     Immunotopics, CA, USA. 
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PCR purification kit     Qiagen, Hilden, Germany. 
Photometric kit    Roche Manheim Germany. 
Plasma leptin ELISA kit,   Linco, St. Charles, USA. 
Primer mix      Search LC, Heidelberg, Germany. 
rabbit anti-B0AT1     Alpha Diagnostics, San Antonio, TX, USA. 
rabbit anti-EAAC1/ EAAT3   Alpha Diagnostics, San Antonio, TX, USA. 
rabbit anti-SIT    Alpha Diagnostics, San Antonio, TX, USA. 
RIA kit, Demeditec    Kiel, Germany. 
RNAeasy Mini Kit    Qiagen, Hilden, Germany. 
Superscript II reverse transcriptase  Invitrogen, Karlsruhe, Germany. 
Trizol reagent Invitrogen   Karlsruhe, Germany. 
 
2.1.4 Animals 
All animal experiments were conducted according to the guidelines of the American 
Physiological Society and the German law for the care and welfare of animals and were 
approved by local authorities. 
 
2.1.4.1 PDK1 hypomorphic mice 
Generation and basic properties of PDK1 hypomorphic mice have been described (41). 
Genotyping was made by PCR on tail DNA using PDK1 and neo-R-specific primers as 
previously described (41;83). Intestinal segments were obtained from 3-8 month old wild-
type mice of a mixed Sv129J/C56Bl/6 background, to reduce the impact of a specific 
genetic background. Comparisons have always been made within the same mouse to 
avoid any bias by variability of mice. Prior to removal of the organ, the animals had free 
access to standard mouse diet, mice had free access to standard mouse diet (C1310, 
Altromin, Langen, Germany) and tap water. 
 
2.1.4.2 Sgk1/ Sgk3 KO mice 
Mice deficient in SGK1 (sgk1-/-) and SGK3 (sgk3-/-) were generated as described 
previously (61;84).Genotyping was made by PCR on tail DNA using SGK3 and neo-R-
specific primers as previously described (57). Mice have always been reproduced by 
heterozygous crossing. Therefore, the genetic background of the animals was a mix of 
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Sv/J129 and C57BL/6. Mice had free access to a standard mouse diet (C1310 Altromin, 
Heidenau, Germany) and tap water.  
 
2.1.4.3 Standard diet 
Standard diet C1310/1314 [0.24% Na+, 0.71% K+, 0.95% Ca2+ (wt/wt)] Altromin, 
Heidenau, Germany. 
Control diet C1000 [0.24% Na+, 0.71% K+, 0.95% Ca2+ (wt/wt)] Altromin, Germany 
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2.2 Methods 
2.2.1 Transepithelial Measurements using - the Ussing Chamber 
Hans Ussing worked out the following concept to measure transepithelial transport in 
1957: With a piece of epithelium the measurement chamber is divided into two halves. 
One can separately supply each half of the chamber with experimental solutions. Thereby 
one can distinguish between basolateral and apical effects, because the epithelium (still 
intact) continues transporting water and ions. The short circuit current which occurs 
during this procedure can be measured directly. To do that, one clamps the voltage above 
the epithelium to zero and measures the necessary current Isc by an external measuring 
circuit. Alternatively one can clamp the current to zero and can then calculate the 
equivalent Isc. This is less harmful for the epithelium. The latter „open circuit“ 
configuration is the method that we used in our experiments. For this purpose an impulse 
generator (Dr. F.Grahammer, Physiologisches Institut Tübingen/Freiburg) generates the 
injection current (I0) at prespecified intervals via Ag-Ag-Cl-electrodes. Depending on the 
resistance of the epithelium the injection current then causes a voltage drop (? Vte) over 
the epithelium. The measurement of Vte and ?Vte occurres via two Ag-Ag-Cl-agar bridges 
with a highly resistant voltmeter that is switched parallel to the epithelium. During the 
intervals without a current impulse the voltmeter registered the spontaneous transepithelial 
potential Vte which is built up through the active transport of ions. When there is a current 
injection then the voltmeter  registers ? Vte. Both are recorded using the computer program 
chart 4.2 (Microsoft) and data are evaluated later after data transferinto excel (Microsoft). 
The resistence of the empty chamber was subtracted from the resistance of the epithelium, 
and the voltage zero was averaged before and after the experiment. With these data one 
can calculate the transepithelial resistance 
Rte = ?Vte/I0 
and the equivalent short-circuit current Isc = Vte/ Rte by the means of Ohm’s law. 
Only tissue samples with a transepithelial resistance > 10 ? *cm2 were taken for data 
analysis. We used a modified and perfused miniature Ussing chamber (85;86) for our 
measurements. We could use extremely small tissue samples, because the opening of the 
chamber had a surface of only 0.00769 cm2. The biopsates were clamped on the chamber 
application with a screw by lowering a drilled metal plate. This construction was then 
inserted in the actual chamber. The volume of the chamber was 3.80 ml and was 
continuously perfused with 5-6 ml/min. The solution and the chamber were both 
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thermostated at 37 °C. The injection current of 1 µA was applied every 6 s for 1 s. 
Figure 3 Schematic construction of the miniature Ussing chamber. 
A screw clamps the jejunum/colon mucosa on the chamber application (1) which is 
inserted into the chamber (4). Both sides of the epithelium are continuously perfused with 
experimental solution. The current I0 is injected via electrodes of silver filament (3). The 
voltage drop ? Vte 
is then recorded by a agar bridge with 1 M KCl-solution and a dipped Ag-AgCl- 
electrode (2). 
 
(6)
(2)
(4)
(3)
(7)
UssingchamberR.R
(1)
(5)
.
A
B
 
Figure 3. Miniature ussing chamber. 
A.Original photograph of Ussing Chamber. B. Schematic structure of the miniature Ussing Chamber. 
(1) Tissue holder, (2) Agar Electrode, (3)Ag/AgCl Electrode, (4) Half Chamber, (5) Inflow, (6) Outflow, (7) 
heated socket. 
2.2.2 Ussing chamber experiments in small intestine 
For analysis of electrogenic intestinal glucose and amino acid transport, animals were 
sacrificed, the abdomen opened and the intestine was quickly removed. Two adjacent 
jejunal segments (5 to 10 cm post pylorus) were mounted onto two identical custom-made 
mini-Ussing chambers with an opening diameter of 0.99 mm and an opening area of 
0.00769 cm2 allowing simultaneous measurements of potential difference and resistance. 
Both chambers were first perfused with control solution from both the serosal and the 
luminal side. The perfusate contained (in mM): 115 NaCl, 2 KCl, 1 MgCl2, 1.25 CaCl2, 
0.4 KH2PO4, 1.6 K2HPO4, 5 Na pyruvate, 25 NaHCO3, 20 Mannitol. All solutions were 
gassed with 95% O2 / 5%CO2 for at least 60 min until usage in the experiment. The pH of 
the perfusates, determined immediately prior to the experiments, was 7.4. The small size 
of the chamber favored an underestimation of the transepithelial resistance (87), yielding 
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values lower than those reported previously (88). The present study addressed relative 
changes of currents, which were not affected by this bias. After stabilization of the tissues 
in the chamber, one chamber was incubated with the PI3-Kinase inhibitor Wortmannin (1 
µM) or LY294002 (50 µM) by continuous perfusion from the serosal side for 15 - 60 min. 
The other chamber was perfused with control solution. 
To test for electrogenic transport of glucose or amino acids, D-glucose, L-phenylalanine, 
L-cysteine, L-glutamine or L-proline (20 mM, all from Roth, Karlsruhe, Germany) were 
added to the luminal perfusate at the expense of mannitol in both chambers. Substrates 
were simultaneously and repeatedly administered over the next 40 min allowing paired 
comparison between the responses in the two chambers. 
 
2.2.3 Terminal uridine deoxynucleotidyl transferase nick - end labeling 
TUNEL staining 
Cryosections of jejunum were analyzed for apoptotic cells by transferase (TdT)-mediated 
deoxyuridine-triphosphate (dUTP) nick-end labeling (TUNEL) method with the In Situ 
Cell Death Detection Kit (Roche Applied Sciences, Mannheim, Germany). Jejunal tissues 
were fixed in para-formaldehyde solution (4% PFA in phosphate buffered saline) for 30 
min and frozen in O.C.T. compound (Tissue-Tek; Sakura Finetek, Heppenheim, 
Germany). Sections of 12 µm thickness were sliced on a freezing microtome, mounted on 
silane coated slides (2 % 3-aminopropyltriethoxy-silane (Sigma, Taufkirchen, Germany) 
in acetone), and dried at room temperature for 1 h. After washing in PBS for 30 min, 
tissue was fixed again in 4 % PFA for 20 min. Afterwards, tissues were incubated with 
proteinase K solution (10 µg/ml in Tris buffer, Roche) for 15 min at room temperature and 
permeabilized with 0.1 % sodium citrate/0.1 % Triton-X-100 (Sigma) for 2 min on ice. 
For the positive control sections were treated with DNase I solution (10 µg/ml in 50 mM 
Tris-HCl/1mg/ml BSA, pH 7.5, Sigma) for 30 min at 37°C. After washing with PBS, 
slides were incubated with only one-fourth of the manufacturer’s recommended 
concentration of enzyme labeling solution for 1 h at 37°C. For the negative control 
transferase enzyme solution was omitted. After washing with PBS, slides were 
additionally stained with phosphate buffered DAPI (4'-6-Diamidino-2-phenylindole) 
solution (1 µg/ml, Sigma) for 10 min. Afterwards, slides were washed three times in PBS, 
briefly rinsed in distilled water, dried and coverslipped with Kaiser’s gelatine (Merck, 
Darmstadt, Germany). Representative areas were photographed with an inverted 
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fluorescence microscope (Axiovert, Zeiss, Jena, Germany). 
 
2.2.4 Glucose load and glucose excretion 
For determination of glucose tolerance and renal glucose excretion unfasted mice were 
injected with 3 mg/g bw glucose in a volume of 30 µl aqua ad iniectabilia/g bw 
intraperitoneally (i.p.). Control experiments in both genotypes were performed injecting 
30 µl 0.9 % NaCl / g bw. Blood glucose was measured from tail-vein blood using a 
glucometer (Accutrend, Roche, Mannheim, Germany) before and at 30, 60 and 120 
minutes after the injection of glucose. Throughout the experiment mice were placed in 
individual metabolic cages (Tecniplast, Hohenpeißenberg, Germany) for the collection of 
a spot urine sample after injection over the next 3 hours yielding 0.1-1.8 ml urine. Urinary 
glucose and creatinine concentrations were determined utilizing commercial enzymatic 
kits: gluco-quant®, Roche Diagnostics, Mannheim, Germany, based on the hexokinase 
method and creatinine PAP, Labor & Technik, Berlin, Germany, based on the creatininase 
method. For quantitative analysis of glucosuria the ratio between glucose and creatinine 
concentration was calculated (in mg glucose/ mg creatinine) to adjust for differences in 
urinary dilution. 
 
2.2.5 Food intake, fecal weight and electrolyte composition 
Mice were placed in individual metabolic cages (Tecniplast, Hohenpeißenberg, Germany). 
After a training period of two days food and fluid intake as well as urinary and fecal 
output were determined under control conditions (Control diet C1000 Altromin, 
Germany) over two consecutive 24 h periods. Results were averaged for each animal. The 
inner wall of the metabolic cages was siliconized and urine was collected under water-
saturated oil to allow for quantitative measurements. Before and at the end of the 
metabolic cage experiments about 150 µl blood was withdrawn into heparinized 
capillaries by puncturing the retro-orbital plexus. Haematocrit was determined after 
centrifugation. Plasma was separated for further analysis. Serum IGF 1 was measured 
using an ELISA kit according to the manufacturer instructions (DSL-10-2900, dsl, 
Webster, USA). 
To determine amino acid concentrations in urine, mice were individually placed in 
metabolic cages and urine was collected quantitatively over 24 h. To prevent bacterial 
growth and hence metabolism and breakdown of amino acids 5 µl of concentrated acetic 
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acid was added into the urine collectors beneath the mineral oil. Amino acid 
concentrations in urine and serum were measured by HPLC as described before (15). 
Urinary creatinine concentrations were determined utilising a commercial enzymatic kit 
(Labor und Technik, Berlin, Germany). 
After a training period of two days food and fluid intake as well as urinary and fecal 
output were determined over three consecutive 24h periods and results were averaged for 
each animal. Feces were dried for 3h at 80°C, weighed and suspended in 0.75 N nitric 
acid. Over two days this mixture was alternately put on a shaker at room temperature or 
into a 50°C water bath for 12h. After centrifugation Na+ and K+ content was determined in 
the supernatant with a flamephotometer (Eppendorf FCM 6341, Germany). Phosphorus 
(Pi) concentration was determined using a photometric kit (Roche) following the 
manufacturer’s manual. 
 
2.2.6 Collection and preparation of feces 
For the analysis of fecal Na+ and K+ excretion feces was collected in metabolic cages 
(Tecniplast, Hohenpeissenberg, Germany). Before the collection, the standard mouse diet 
was switched to a control diet for 1 week (C1000, measured Na+ content 120µmol/g food, 
Altromin, Heidenau, Germany) and the animals were placed individually in metabolic 
cages for 24 hour feces collection.  
To investigate the effects of salt depletion, feces was collected for two days under the 
control diet and access to distilled water preventing compensatory sodium intake by tap 
water (Na+ content 1mM). After switching the animals to the low salt diet (C1036, 
Altromin, Heidenau, Germany), a second feces collection was made on the fourth and 
fifth day. For final data analysis the average of the two days under the respective diet was 
taken.  
To investigate the effects of a 4 day treatment with dexamethasone (10µg/g bw) on fecal 
Na+ and K+ excretion, feces was collected 1 day before treatment and on the 4th day of 
treatment under control diet (C1000) and tap water. 
 
2.2.7 Electrogenic glucose and amino acid transport in isolated perfused 
proximal straight tubules 
Experiments were performed in proximal straight tubules. Segments of 0.2 to 0.4 mm 
length were dissected and perfused following principally the method of Burg et al. (89). 
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Modifications of the technique concerning track system, pipette arrangement and use of 
dual channel perfusion pipettes have been described in detail previously (90;91). The 
luminal perfusion rate was < 10 nl/min. The bath was continuously perfused at a rate of 20 
ml/min and thermostated with a dual channel feedback system (Hampel, Frankfurt, 
Germany). The bath temperature was kept constant at 38 0C. The potential difference 
across the basolateral cell membrane (PDbl) was determined utilizing Ling-Gerard 
electrodes (100-200 MO) pulled from filament capillaries (1.5 o.d., 1.0 i.d., Hilgenberg, 
Malsfeld; Germany). The electrodes were connected to a high impedance electrometer 
(FD223, WPI, Science Trading, Frankfurt, Germany) via an Ag/AgCl half cell. An 
Ag/AgCl reference electrode was connected with the bath. Entry of positive charge by 
electrogenic transport is expected to depolarize the basolateral cell membrane. The 
magnitude of the depolarization depends on the magnitude of the induced current on the 
one hand and on the resistances of cell membranes and shunt on the other. PDbl was 
continuously recorded with and without Glucose, L-phenylalanine, L-glutamine or L-
proline (20 mM each) in the luminal perfusate to stimulate electrogenic reabsorption as 
described (92). The bath and luminal perfusates were composed of (all numbers mM): 110 
NaCl, 5 KCl, 20 NaHCO3, 1.3 CaCl2, 1 MgCl2, and 2 Na2HPO4. In the bath, (in mM) 18 
mannitol, 1 glucose, 1 glutamine and 1 Na- lactate and in the lumen 20 mannitol and 1 
Ba2+ were added. Where indicated, 20 mM mannitol were replaced by 20 mM of the 
respective amino acid in the luminal perfusate. The bath solution was constantly gassed 
with a mixture of 95% O2 and 5% CO2 resulting in a pH of 7.4. 
 
2.2.8 Preparation of Brush Border Membrane Vesicles (BBMV)  
BBMV were prepared from whole mouse kidney using the Mg2+- precipitation technique 
as described previously (93) After measurement of the total protein concentration (Biorad 
Protein kit), 20 µg of brush border membrane protein were solubilized in Laemmli sample 
buffer, and SDS-Page was performed on 10 % polyacrylamide gels. For immunoblotting, 
proteins were transferred electrophoretically from unstained gels to PVDF-membranes 
(Immobilon-P, Millipore, Bedford, MA, USA). After blocking with 5 % milk powder in 
Tris-buffered saline/0.1% Tween-20 for 60 min., the blots were incubated with affinity 
purified rabbit anti-B0AT1 (SLC6A19), rabbit anti-SIT (SLC6A20) (50), rabbit anti-
EAAC1/ EAAT3 (SLC1A1) (Alpha Diagnostics, San Antonio, TX, USA), rabbit anti-
b0,+AT1 (SLC7A9) (Pfeiffer et al. 1999 antibodies (1:1000) and mouse monoclonal anti-
actin (42 kDa, Sigma) 1: 500 either for 2 h at room temperature or overnight at 4 °C. After 
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washing and subsequent blocking, blots were incubated with secondary antibodies 
conjugated with alkaline phosphatase or horse radish peroxidase (goat anti-rabbit 1: 5000 
and donkey anti-mouse 1: 5000 (Promega)), for 1 h at room temperature. Antibody 
binding was detected with the enhanced chemiluminescence kit (Pierce) in the case of 
HRP-linked antibodies and with the CDP Star kit (Roche, USA) for AP linked antibodies 
before detection of chemiluminescence with the Diana III Chemiluminescence detection 
system. Bands were quantified with the Aida Image Analyzer software (Raytest, 
Germany). 
 
2.2.9 In situ Hybridisation  
DIG-labeled, SGK3-specific, antisense and sense RNA probes were generated from RT-
PCR derived templates by in vitro transcription. Total cellular RNA was prepared from 
adult mouse hippocampus by us ing Trizol reagent (Invitrogen, Karlsruhe, Germany). 
After treatment with RNase-free DNase, the first-strand oligo (dT)-primed cDNA was 
synthesized with Superscript II reverse transcriptase (Invitrogen). Afterwards, PCR 
amplification of a 470-bp specific DNA fragment of SGK3 sequence was performed with 
following primers: SGK3 forward: 5’ CAGAAAACAGCCCTATGACAACAC 3’; SGK3 
reverse: 5’ GAGGGGCGTAAGAAAAACCAACA 3’. PCR was carried out under 
following conditions: 95 °C for 10 min, 35X (95 °C for 30 s, primer annealing at 58 °C 
for 45 s, 72 °C for 45 s) and 72 °C for 10 min. AmpliTaq DNA polymerase and PCR 
reagents were purchased from Applied Biosystems (Lincoln, USA). In order to produce a 
DNA template for the generation of antisense and sense RNA probes by in vitro 
transcription, T7 RNA polymerase promoter sequence was added to the 5' end of PCR 
product by a further PCR reaction under the same PCR conditions, described above. 
Primer sequences are shown below, whereby promoter sequences are underlined: For 
generation of sense probe: T7_SGK3 forward: 5’ 
GCAGTAATACGACTCACTATAGGGCAGAAAACAGCCCTATGACAACAC 3’; 
SGK3 reverse: 5’ GAGGGGCGTAAGAAAAACCAACA 3’; For production of antisense 
probe: SGK3 forward: 5’ CAGAAAACAGCCCTATGACAACAC 3’; SGK3_T7 reverse: 
5’ GCAGTAATACGACTCACTATAGGGGAGGGGCGTAAGAAAAACCAACA 3’. 
Afterwards, PCR fragments were purified with a PCR purification kit (Qiagen, Hilden, 
Germany). In vitro transcription was performed with the DIG-labeling kit (Roche 
Molecular Biochemicals, Mannheim, Germany) by using 100 ng template DNA. After 
ethanol precipitation, labeled RNA probe was quantified by dot blot according to the 
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protocol of the DIG-labeling kit. 
 
2.2.10  Quantitative real -time PCR measurements 
To test whether colonic SGK1 transcription is up-regulated by dexamethasone and 
DOCA, wild-type mice underwent a four day treatment with dexamethasone (10µg/g bw 
s.c.) or a seven day treatment with DOCA (1.5mg/day in 50µl DMSO). To obtain colonic 
tissue treated and untreated wildtype animals were deeply anesthetized with diethylether 
and killed by cervical dislocation and the abdomen was opened. The intestine was quickly 
removed and carefully flushed with 4°C control buffer to remove remaining food 
particles. Specific intestinal segments were rapidly frozen in liquid nitrogen. Automated 
disruption and homogenization of frozen tissue was performed using the MagNa Lyser 
Instrument (Roche Diagnostics, Mannheim, Germany). For each sample one-way special 
tubes containing ceramic beads were filled with 20-30 mg of frozen tissue and 600 µl of 
RLT-buffer (Qiagen, Hilden, Germany). Cleared cell lysate was transferred for further 
RNA purification (RNAeasy Mini Kit, Qiagen, Hilden, Germany). Subsequently 1 µg of 
total RNA was reverse transcribed to cDNA utilizing the reverse transcription system 
(Bioscience, USA) with oligo (dT) primers according to the manufacturer’s protocol. To 
determine mSGK1 mRNA levels, quantitative real-time PCR with the LightCycler System 
(Roche Diagnostics, Mannheim, Germany) was established. PCR reactions for mSGK1 
were performed in a final volume of 20 µl containing 2 µl cDNA, 2.4 µl MgCl2 (3 µM), 1 
µl primermix (0.5 µM of both primers), 2 µl cDNA Master SybrGreen I mix (Roche 
Molecular Biochemicals, Mannheim, Germany) and 12.6 µl DEPC treated water. The 
transcript levels of the housekeeping gene mGAPDH were also determined for each 
sample using a commercial primer kit (Search LC, Heidelberg, Germany). PCR reactions 
for GAPDH were performed in a final volume of 20 µl containing 2 µl cDNA, 2 µl primer 
mix (Search LC, Heidelberg, Germany), 2 µl cDNA Master Sybr Green I mix (Roche 
Molecular Biochemicals, Mannheim, Germany) and 14 µl DEPC treated water.  
Amplification of the target DNA was performed during 35 cycles of 95°C for 10s, 68°C 
for 10s and 72°C for 16s, each with a temperature transition rate of 20°C/s and a 
secondary target temperature of 58°C with a step size of 0.5°C. Melting curve analysis 
was performed at 95°C 0s, 58°C 10s, 95°C 0s to determine melting temperatures of 
primer dimers and the specific PCR products. Melting curve analysis confirmed the 
amplified products, which were then separated on 1.5% agarose gels to confirm the 
expected size (406 bp). Finally, results were calculated as a ratio of the target vs. house 
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keeping gene transcripts.  
The following primers for mSGK1 (Gene bank No.: NM_011361) were used:  
mSGK1 sense:5’-TGT CTT GGG GCT GTC CTG TAT G-3’ 
mSGK1 antisense:5’-GCT TCT GCT GCT TCC TTC ACA C-3’ 
 
2.2.11 In situ hybridization of SGK3 mRNA. 
Adult mice (C57/BL6 wild type and SGK3-/-) were deeply anesthetized with 
ketamine/xylazine. Large and small intestine were removed, immediately frozen in  25°C 
cold isopentane and sliced on a freezing microtome at 12 µm thickness. Sections were 
subsequently mounted on silane coated slides (2% 3-aminopropyltriethoxy-silane (Sigma, 
Taufkirchen, Germany) in acetone), dried at 60 °C for 30 s and fixed with 4% phosphate 
buffered paraformaldehyde for 20 min. After three washes with phosphate buffered saline 
(PBS, 0.1 mM, pH 7.4), slides were incubated with TE buffer (100 mM Tris, 50 mM 
EDTA, pH 8) containing 2 µg/ml proteinase K for 10 min at room temperature and rinsed 
again three times with PBS. In order to reduce nonspecific background, slides were 
acetylated with TEA buffer (0.1 M triethanolamine, pH 8.0) containing 0.25% (v/v) acetic 
anhydride (Sigma) twice for 5 min. After pre-hybridization with hybridization buffer 
(50% formamide (Sigma), 10 % dextran sulfate, 5 mM EDTA, 20 mM Tris pH 8, 10 mM 
DTT, 1X Denhardt’s solution, 0.05 % tRNA, 300 mM NaCl) for 1 h at 62 °C, sections 
were incubated with fresh hybridization buffer containing the denatured DIG-labeled 
sense or antisense probe (200 ng/ml) overnight at 62 °C. After hybridization, slides were 
briefly rinsed in 2X SSC at room temperature and 3 times in 0.1X SSC for 15 min at 62 
°C. Detection of DIG-labeled RNA probe was performed according to the protocol of the 
DIG nucleic acid detection kit (Roche, Basel Schwitzerland). The tissues were blocked for 
30 min with blocking buffer (1% blocking reagent (Roche) in maleic acid buffer (0.1 M 
maleic acid, 0.15 M NaCl, pH 7.5) and then incubated with alkaline phosphatase-
conjugated antibody solution (anti-DIG antibody (1:2500 Roche) in blocking buffer 
containing 0.1% Triton® X 100) for 1 h. Following 4 washes with maleic acid buffer for 
15 min, slides were equilibrated for 5 min in Tris buffer pH 9.5 (0.1 M Tris, pH 9.5, 0.1 M 
NaCl, 50 mM MgCl2). The colour development was carried out with freshly prepared 
substrate solution (nitroblue tetrazolium salt (NBT) and 5-bromo-4-chloro-3-indolyl 
phosphate (X-phosphate) (Roche) in Tris buffer pH 9.5). After 3 washes with PBS, slides 
were rinsed in distilled water, dried, and coverslipped with Kaiser’s solution (Merck, 
Darmstadt, Germany). 
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2.2.12 Dexamethasone, DOCA and low salt treatment 
For analysis of glucocorticoid effects on colonic ENaC activity, sgk1+/+ and sgk1-/- mice 
(3-12 months old, both genders) were injected subcutaneously with dexamethasone 
phosphate disodium salt (Sigma, Taufkirchen, Germany; dissolved in 0.9% saline) at a 
dose of 10µg/g BW for four consecutive days at 8 pm. sgk1-/- and sgk1+/+ mice injected 
with 0.9% saline alone served as controls. This regimen had previously shown marked up-
regulation of intestinal SGK1 (94) but was tolerated by the mice seemingly well. Mice 
had free access to a standard mouse diet (C1310, Altromin, Heidenau, Germany) and tap 
water.  
For analysis of mineralocorticoid effects, sgk1+/+ and sgk1-/- mice were treated with 
intraperitoneal injections of DOCA (Sigma, Taufkirchen, Germany) at a dose of 1.5mg 
per day dissolved in 50µl DMSO for seven consecutive days. This dose was adapted 
according to a previous study (95)and was tolerated by the mice seemingly well. Again, 
mice had free access to a standard mouse diet (C1310, Altromin, Heidenau, Germany) and 
tap water.  
To analyze the effects of salt depletion, the standard mouse diet (C1310, measured Na+ 
content 82 µmol/g, Altromin, Heidenau, Germany) was replaced by low salt diet (C1036, 
measured Na+ content 7.3 µmol/g food, Altromin, Heidenau, Germany). Animals were 
sacrificed for Ussing chamber experiments after 7 days of treatment. 
 
2.2.13  Plasma aldosterone measurements 
Blood specimens were obtained during light anesthesia with diethylether (Roth, 
Karlsruhe, Germany) and approximately 150 µl of blood was drawn into heparinized 
capillaries by puncturing the retro-orbital plexus. Plasma aldosterone concentrations were 
measured using a commercial RIA kit (Demeditec, Kiel, Germany). 
 
2.2.14  Intestinal NHE3 activity. 
 For isolation of ileal villi, animals were fasted for 6 h before experiments. After the death 
of the animals, the terminal 2 cm of the ileum were removed and cut longitudinally. After 
being washed with standard HEPES solution, the intestine was sliced into 0.3-cm2 
sections. The tissues were transferred onto the cooled stage of a dissecting microscope, 
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and individual villi were detached from the intestine by snapping off the ileal base with 
sharpened microdissection tweezers. Care was taken not to damage the apical part of the 
villi. The villi were attached to a glass coverslip precoated with Cell-Tak adhesive (BD 
Biosciences, Heidelberg, Germany). For quantitative digital imaging of intracellular pH 
(pHi), isolated individual villi were incubated in a HEPES-buffered Ringer solution 
containing10 µM 2',7'-bis-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF)-AM 
(Molecular Probes, Leiden, The Netherlands) for 15 min at 37°C. After being loaded, the 
chamber was flushed for 5 min with Ringer solution to remove any deesterified dye 
sticking to the outside of the villi. The perfusion chamber was mounted on the stage of an 
inverted microscope (Zeiss Axiovert 135, Oberkochen, Germany), which was used in the 
epifluorescence mode with a 40 oil- immersion objective (Zeiss Neoplan, Oberkochen, 
Germany). BCECF was successively excited at 490 ± 10 and 440 ± 10 nm, and the 
resultant fluorescent signal was monitored at 535 ±10 nm via an intensified charge-
coupled device camera (Proxitronic, Bensheim, Germany) and specialized computer 
software (Metafluor, Universal Imaging, Downingtown, PA). Individual regions of 
interest at the tip of the villi were outlined and monitored during the course of the 
measurement. Intensity ratio data (490/440) were converted into pH values by the high-K 
/nigericin calibration technique (96).  
The solutions, flow lines, and perfusion chamber were maintained at 37°C by a 
thermostatically controlled heating system. The volume of the perfusion chamber was 600 
µl and the flow rate was 4 ml/min for all solutions. For acid loading, cells were transiently 
exposed to a solution containing 20 mM NH4Cl leading to marked initial alkalinization of 
pHi due to entry of NH3 and binding of H+ to form NH4+ (97). The acidification of pHi 
upon removal of ammonia allowed us to calculate the mean intrinsic buffering power (ß) 
of the cells (97), assuming that NH4+ and NH3 are in equilibrium in cytosolic and 
extracellular fluid and that ammonia leaves the cells as NH3 :  
ß = ?[NH4+]i / ? pHi 
where ?pHi is the decrease of pHi after ammonia removal and  ?[NH4+] i is the decrease 
of cytosolic NH4+ concentration, which is identical to the concentration of NH4+   
immediately before the removal of ammonia. Given the pK for NH4+ /NH3 of 8.9 (98), an 
extracellular pH (pH0) of 7.4 and an NH4+   concentration in extracellular fluid ([NH4+]0) 
of 19.37 [20/(1 +10pHo- pK)], then [NH4+]i =19.37 x10 pHo- pK. 
 For some experiments, the selective NHE3 inhibitor S3226 (Aventis, Frankfurt, Germany) 
was added to all solutions at a concentration of 10µM.The solutions were composed of the 
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following (in mM): for standard HEPES, 115 NaCl, 5 KCl, 1 CaCl2, 1.2 MgSO4, 2 
NaH2PO4, 10 glucose and 32.2 HEPES; for sodium-free HEPES, 132.8 NMDG, 3 KCl, 1 
CaCl2, 1.2 MgSO4, 2 KH2PO4, 32 HEPES, 10 mannitol, and 10 glucose; for sodium-free 
ammonium chloride, 15 NMDG-Cl and 10 mannitol were replaced by 20 mM NH4Cl; and 
for calibration, 105 KCl, 1 CaCl2, 1.2 MgSO4, 32.2 HEPES, and 10 mannitol (5 M 
nigericin). The pH of the solutions was titrated to 7.4 or 7.0 with HCl-NaOH, HCl-
NMDG, and HCl-KOH, respectively, at 37°C. All substances were from Sigma 
(Taufkirchen, Germany) or Roth (Karlsruhe, Germany). SDS-PAGE and Western blot 
analysis. 
 
2.2.15 Statistics 
Data are provided as means ± SEM, n represents the number of independent experiments. 
All data were tested for significance using paired or unpaired Student´s t-test with or 
without Welch´s correction or Mann-Whitney test where applicable, and only results with 
P < 0.05 were considered statistically significant. 
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3 Results 
3.1 PI3-kinase-dependent glucose and amino acid transport 
3.1.1 Glucose and amino acid transport  
To determine PI3-kinase-dependent glucose and amino acid transport in wild-type mice, 
segments of jejunum were mounted onto mini-Ussing chambers for electrophysiological 
analysis. Simultaneous measurements with one control chamber and one chamber 
incubated with the PI3 kinase inhibitor Wortmannin. allowed paired comparison between 
control and treatment. In the absence of luminal substrates, the transepithelial potential 
difference (Vte) of all studied jejunal segments (n = 22) amounted to -0.39 ± 0.10 mV and 
the transepithelial resistance (Rte) approached 6.1 ± 0.3 O cm2. The values allowed the 
calculation of the basal short circuit current (Isc), which approached -55 ± 15µA/cm². 
Neither transepithelial potential difference (-0.50 ± 0.12 mV) nor transepithelial resistance 
(5.8 ± 0.4O cm2) were significantly altered 55 minutes after the application of 1 µM 
Wortmannin (n = 22). Accordingly, Isc was similarly not significantly affected by the PI3- 
kinase inhibitors (-90 ± 24 µA/cm²). 
The isoosmotic replacement of mannitol by glucose generated a lumen-negative shift of 
the transepithelial potential difference (? Vglc) without significantly altering the 
transepithelial resistance (Fig. 4.) The ? Vglc and Rte allowed the calculation of the 
glucose- induced current (Iglc), which approached -1353 ± 216 µA/cm2 under control 
conditions, i.e. in the absence of Wortmannin (Fig. 4, n=5). Throughout the course of the 
experiment Iglc remained constant in the control chamber. In contrast, Iglc gradually 
declined in segments incubated with 1µM Wortmannin. Within 40 min Iglc was only 61 ± 
12 % of the control value (Fig. 4). 
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Figure 4. Effect of Wortmannin on glucose-induced current in jejunal  segments . Alterations of 
transepithelial voltage (?Vglc) and glucose-induced currents (Iglc) in proximal segments of jejunal tissue with 
or without ncubation with Wortmannin (1 µM).  
A Original tracings illustrating the effect of 20 mM glucose on the transepithelial potential difference in the 
absence (upper panel) and presence (lower panel) of Wortmannin.  
B Arithmetic means±SEM (n=5) of glucoseinduced currents (µA/cm2) following exposure to perfusate with 
Wortmannin (closed bars) or without Wortmannin (open bars).  
#Significant difference between presence and absence of Wortmannin.  
C Arithmetic means ± SEM (n=5) of glucoseinduced current, in percent of the currents in the beginning of 
the experiment, following exposure to perfusate with Wortmannin (closed symbols) or without Wortmannin 
(open symbols).  
#Significant difference between presence and absence of Wortmannin 
 
Similar to glucose, the amino acids phenylalanine, cysteine, glutamine or proline 
generated a lumen-negative shift of the transepithelial potential difference (? Vaa) without 
significantly altering the transepithelial resistance. The ? V and Rte allowed the calculation 
of the amino acid induced current (Fig. 5, table 1). 
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Figure 5 Effect of Wortmannin on glutamine-induced current in jejunal segments . Alterations of 
transepithelial voltage (?Vgln) and glutamine induced currents (Igln) in proximal segments of jejunal tissue 
with or without incubation with Wortmannin (1 µM).  
A Original tracings illustrating the effect of 20 mM glutamine on the transepithelial potential difference in 
the absence (upper panel) and presence (lower panel) of Wortmannin.  
B Arithmetic means ±SEM (n=4) of glutamineinduced currents in jejunum following exposure to perfusate 
with Wortmannin (closed bars) or without Wortmannin (open bars). 
# Significant difference between presence and absence of Wortmannin. 
C Arithmetic means ±SEM (n=4) of glutamine-induced current, in percent of the currents in the beginning 
of the experiment, following exposure to perfusate with Wortmannin (closed symbols) or without 
Wortmannin (open symbols).  
# Significant difference between presence and absence of Wortmannin 
Table 1.Amino acid-induced currents following a 40 min treatment with 1 µM Wortmannin  
 Control chamber Chamber incubated with 
Wortmannin 
 initial value after 40min initial value after 40min 
Phenylalanine (n=4) 1046 ± 163 541 ± 137 1013 ± 77 174 ± 59 # 
Glutamine (n=4) 689 ± 88 327 ± 59 821 ± 158 131 ± 36 # 
Cysteine (n=6) 549 ± 91 201 ± 75 528 ± 89 57 ± 47 # 
Proline (n=3) 815 ± 20 443 ± 134 1089 ± 181 208 ± 179 # 
 
Substrate-induced currents (µA/cm2) in the control chamber as well as in the chamber incubated with 
Wortmannin. # indicates significant difference between presence and absence of Wortmannin. 
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The amino acid- induced currents significantly decreased in the control chamber even in 
the absence of Wortmannin. This decrease was, however, significantly accelerated in the 
presence of Wortmannin. Within 40 min Iphe declined by 70 ± 7%, Igln by 69 ± 8%, Icys by 
67 ± 8 %, and Iprol by 79 ± 12%, as compared to the respective currents in the control 
chamber (Fig. 5, table 1). 
As shown for glucose-induced currents, the PI3 kinase inhibitor LY294002 was similarly 
effective as Wortmannin. Following a 15 min preincubation with a luminal fluid 
containing 50 µM LY294002, Iglc gradually declined to 46 ± 9% of the original value 
within 40 min (Fig. 6, n=6).  
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Figure 6 A Effect of LY294002 on glucose-induced current in jejunal segments. Alterations of 
transepithelial voltage (?Vglc) and glucose-induced currents (Iglc) in proximal segments of jejunal tissue with 
or without incubation with LY294002 (50 µM).  
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A Original tracings illustrating the effect of 20 mM glucose on the transepithelial potential difference in the 
absence (upper panel) and presence (lower panel) of LY294002.  
B Arithmetic means ±SEM (n=5) of glucose-induced currents in jejunum following exposure to perfusate 
with Wortmannin (closed bars) or without Wortmannin (open bars).  
#Significant difference between presence and absence of LY294002.  
C Arithmetic means±SEM (n=5) of glucoseinduced currents, in percent of the currents at the beginning of 
the experiment, following exposure to perfusate with Wortmannin (closed symbols) or without Wortmannin 
(open symbols).  
# Significant difference between presence and absence of LY294002. 
 
Additional experiments have been performed to test for forskolin- induced currents. 
Following a 15 minute treatment, the forskolin- induced current was similar in 
Wortmannin treated (701 ± 155 µA/cm2) and solvent treated (700 ± 176 µA/cm2) 
intestine. After 60 minutes treatment, the forskolin- induced currents decreased in both, 
Wortmannin treated (107 ± 27 µA/cm2) and solvent treated (294 ± 55 µA/cm2) intestine. 
After 60 minutes the current was significantly lower in Wortmannin-treated intestine.  
To explore whether the decline of current was the result of tissue injury, additional 
experiments have been performed to elucidate the appearance of apoptosis. As shown in 
Fig. 7, apoptosis was similarly low following a 15 minute treatment of intestine with 
Wortmannin as in untreated time controls. 
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Figure 7. Apoptosis in jejunum in absence and presence of Wortmannin. TUNEL staining of 
representative jejunal gut sections. Only few apoptotic cells (arrowheads) were observed in the control 
tissue (a and d) and in the tissue treated with 1 µM Wortmannin for 15 min (b and e). a, b TUNEL-positive 
nuclei (arrowheads) of untreated (a) and treated tissue (b), respectively. c Sections of positive control 
treated with DNase I. All nuclei of intestinal tissue were TUNEL-positive.The strongly reduced DAPI 
staining of positive control caused by the DNase I treatment is not shown. d, e Fluorescence co-staining for 
DAPI (blue) and TUNEL-positive nuclei (green) of the same area shown in  a and b. Scale bars=50 µm. 
Abbreviations: TM tunica muscularis, SM submucosa, M mucosa 
In contrast, strong TUNEL staining was observed following treatment of the tissue with 
DNase.  
 
3.1.2  PDK1-dependent glucose transport 
To determine PDK1-dependent glucose transport, segments of jejunum from pdk1hm and 
pdk1wt mice were mounted into mini-Ussing chambers and electrogenic glucose transport 
was determined utilizing electrophysiological analysis (Fig. 8).  
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Figure 8. Glucose-induced voltage deflections and currents in jenunal segments . Glucose-induced 
alterations of transepithelial voltages and currents (Iglc) in proximal segments of jejunal tissue from 
phosphoinositide-dependent kinase-1 (PDK-1) hypomorphic (pdk1hm) mice and wild-type littermates 
(pdk1wt) are shown. Glucose (20 mM) was added, replacing 20 mM mannitol.  
A: original tracings illustrating the effect of glucose on the transepithelial potential difference (PD). 
Arithmetic means  SE of Iglc in proximal (B) and distal (C) jejunum from pdk1hm [solid bars, n  10 (B) and 
11 (C)] and pdk1wt [open bars, n  13 (B) and 12 (C)] mice. *Statistically significant (P  0.05) difference 
between pdk1hm and pdk1wt mice. 
The isoosmotic replacement of mannitol by glucose generated a lumen-negative shift of 
the transmural potential difference (? Vglc) without significantly altering the transmural 
resistance. The ? Vglc and Rte allowed the calculation of the glucose induced current Iglc. In 
proximal segments of pdk1hm Iglc amounted to -943 ± 139 µA/cm2 (n = 10) for 20 mM 
glucose. In proximal segments of pdk1wt mice Iglc approached -1507 ± 210 µA/cm2 (n = 
13). As demonstrted in Fig. 8B, the currents were significantly smaller in proximal 
jejunum obtained from pdk1hm than in the proximal jejunum of pdk1wt mice.  
Similar observations were made in distal jenunal segments. In distal segments of pdk1hm 
Iglc amounted to -785 ± 133 µA/cm2 (n = 11) for 20 mM glucose. In distal segments of 
pdk1wt  mice Iglc approached -1291 ± 127 µA/cm2 (n = 12). Again, the currents were 
significantly smaller in pdk1hm than in pdk1wt mice (Fig. 8C).  
According to intracellular impalements, the potential difference across the basolateral cell 
membrane (PDbl) of isolated perfused straight proximal tubules (i.e. late aspects of 
proximal tubule) was in the absence of glucose  was not different between pdk1hm (-54.6 ± 
1.3 mV, n = 7) and pdk1wt (-54.9 ± 2.4 mV, n = 6) mice (Fig. 9).  
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Figure 9. Effect of glucose on the PD across the basolateral cell membrane of straight proximal 
tubules .  
A: original tracings illustrating the effect of glucose on the PD across the basolateral cell  
B: arithmetic means  SE of the glucose-induced depolarization of the basolateral cell membrane from pdk1hm 
(solid bar, n  7) and pdk1wt (open bar, n  6) mice.  
*Statistically significant (P<  0.05) difference between pdk1hm and pdk1wt mice. 
 
Addition of 20 mM glucose to the luminal fluid replacing mannitol significantly decreased 
PDbl in both, pdk1hm and pdk1wt mice, an effect, however, significantly smaller in pdk1hm 
than in pdk1wt mice (Fig. 9).  
PDK1 could regulate electrogenic glucose transport by enhancing expression and/or by 
increasing the activity of expressed protein. To explore the effect of PDK1 on SGLT1 
expression, immunoblotting was performed in brush border membranes of the proximal 
tubule, jejunum and ileum. No significant difference in SGLT1 protein abundance could 
be detected in the brush border membrane fraction obtained from kidney, jejunum, and 
ileum from pdk1hm and pdk1wt mice (n = 5 for each genotype, (Fig. 10).  
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Figure 10 Abundance of sodium-dependent glucose transporter-1 (SGLT-1) in the brush-border 
membrane in kidney, jejunum, and ileum.  
Top: arithmetic means SE of SGLT-1 expression normalized for ß-actin in brush-border membranes 
obtained from kidney, jejunum, and ileum of pdk1hm and pdk1wt 
mice (n 5 each). Bottom: original Western blots of SGLT-1 and -ßactin. 
 
Further experiments were performed to elucidate the plasma concentrations and renal 
excretion of glucose prior to and following a glucose load of 3 g/kg bw. As illustrated in 
(Fig. 9), intraperitoneal injection of glucose led to a transient increase of plasma glucose 
concentration approaching similar values in pdk1hm and pdk1wt mice. 
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Figure 11. Plasma glucose concentrations ([glc]p) following intraperitoneal glucose injection.  
Values are arithmetic means SEM (n  10–12) of [glc]p following intraperitoneal injection of 3 g/kg body wt 
glucose in pdk1hm (solid bar) and pdk1wt (open bar). 
 
The peak glucose concentration tended to be higher and the subsequent decline of plasma 
glucose concentration tended to be slower in pdk1hm than in pdk1wt mice, a difference, 
however, not statistically significant. To explore whether the filtered glucose load during 
the intraperitoneal glucose injection exceeded the maximal renal tubular glucose 
reabsorption, mice were placed in metabolic cages and urinary glucose concentration was 
determined. To account for individual variations of urinary flow rate, the urinary excretion 
of glucose was divided by the respective creatinine excretion. As shown in (Fig. 12 and 
Table 2), intraperitoneal glucose administration led to a transient glucosuria which was 
markedly higher in pdk1hm than in pdk1wt mice. 
 
III                                                                                                                                 Results 
38 
0
2
4
6
8
10
12
14
16
18
20
saline injection glucose injection
U
g
lc
/U
cr
ea
,[
m
g 
g
lc
/m
g 
cr
ea
]
* #
#
U
g
lc
/U
cr
ea
,[
m
g 
g
lc
/m
g 
cr
ea
]
 
Figure 12 Urinary glucose excretion following an intraperitoneal glucose injection .Values are 
arithmetic means  SE (n  9–12) of urinary glucose over creatinine concentration [Uglc/Ucrea] following the 
intraperitoneal injection of 3 g/kg body wt glucose in pdk1hm (solid bar) and pdk1wt (open bar) mice. 
*Statistically significant (P<  0.05) difference between pdk1hm and dk1wt mice. 
#Statistically significant (P< 0.05) increase following glucose injection. 
 
Table 2.Renal excretion of glucose prior to or following a saline or a glucose load of 3 g/kg bw i.p 
 Saline injection Glucose injection 
 pdk1wt pdk1 hm pdk1wt pdk1hm 
BW (g) 28.5 ± 1.0 (12) 21.1 ± 1.0  (12) *  26.6 ± 1.1 (12) # 19.1 ± 1.0 (12) * 
Vu (ml/3h) 0.78 ± 0.13 (12) 0.40 ± 0.10 (12) 0.35 ± 0.05(12) # 0.18 ± 0.04 (10) *  
Ucrea (mg/dl) 11.2 ± 1.6 (12) 12.4 ± 1.9 (12) 15.0 ± 3.4 (12) 12.4 ± 2.5 (9)  
UVcrea (mg/3h/g BW) 2.59 ± 0.29 12) 1.79 ± 0.27 (11) 1.35 ± 0.18 (12) # 0.84 ± 0.12 (10) # 
Uglc (mg/dl) 6.71 ± 0.88 12) 8.38 ± 0.89 (12) 18.07 ± 5.66 (12)  96.62 ± 28.0 (10)  * 
UVglc (mg/3h/g BW) 1.69 ± 0.33 12) 1.27  ± 0.18 (12) 2.79 ± 1.41 (12) 9.19 ± 4.06 (10) 
Uglc/Ucrea (mg glc /mg crea) 0.67 ± 0.09 12) 0.82 ± 0.15 (12) 2.38 ± 0.78 (12) # 13.81 ± 4.56 (10)  * 
 
BW = body weight, Vu = urinary volume Ucrea = urinary creatinine concentration, UVcrea = urinary creatinine 
excretion, Uglc = urinary glucose concentration, UVglc = urinary glucose excretion  
# statistically significant (p<0.05) difference between saline and glucose injection * statistically 
significant (p<0.05) difference between pdk1hm and pdk1wt mice. 
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3.1.3 PDK1-dependent amino acid transport  
As reported earlier, at the same age (32-36 weeks) body weight was significantly smaller 
in pdk1hm mice (22.5 ± 0.9 g, n = 12) than in pdk1wt mice (32.7 ± 1.3 g, n = 12). Despite 
lower body weight of pdk1hm mice, food and water intake were similar in pdk1hm mice 
(3.8 ± 0.2 g/24h and 4.4 ± 0.4 ml/24h, respectively) as in pdk1wt mice (3.2 ± 0.1 g/24h and 
4.2 ± 0.5 ml/24h, respectively). Consequently, if expressed per g body weight, food and 
water intake were significantly larger in pdk1hm than pdk1wt mice (Fig. 13).  
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Figure 13. Body weight, food and water intake (per 24h) in pdk1hmand pdk1wt mice. Arithmetic means ± 
SE (n=12) of body weight, food and water intake of PDK1 hypomorphic mice (pdk1hm, filled columns) and 
WT littermates (pdk1wt, open columns).  
*Statistically significant difference between pdk1hm and pdk1wt 
 
In theory, growth retardation could result from defective release of growth hormone 
leading to decreased formation of IGF1. To explore this possibility, we determined plasma 
IGF-1 concentrations in both, weaning (18 days) and adult (4 months) animals. The 
respective values were, however, not significantly different between pdk1hm mice (338 ± 
43 ng/ml and 454 ± 44 ng/ml, respectively, n=7-9) and pdk1wt mice (332 ± 13 ng/ml and 
483 ± 64 ng/ml, respectively, n=7-9). 
Further experiments were performed to determine whether altered weight was paralleled 
by altered intestinal transport. To determine PDK1-dependent amino acid transport, 
corresponding segments of jejunum from pdk1hm and pdk1wt mice were mounted into 
mini-Ussing chambers and electrogenic amino acid transport was determined utilizing 
electrophysiological analysis (Fig. 14). 
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Figure 14. Amino acid-induced short circuit current (Isc, aa) in proximal jenunal segments . Alterations 
of transepithelial voltages (DVaa) and induced short circuit currents (Isc,aa) in proximal segments of jejunal 
tissue from PDK1 hypomorphic mice (pdk1hm) and WT littermates (pdk1wt) before and after addition of 
phenylalanine (Phe), cysteine (Cys), glutamine (Gln), proline (Pro), leucine (Leu), tryptophan (Try), 
methionine (Met), valine (Val), and citrulline (Cit).  
A) Original tracings illustrating the effect of amino acids on the transepithelial potential difference.  
B) Arithmetic means ± SE (n13–14) of amino acid-induced short circuit currents in jejunum from pdk1hm 
mice (open columns) and pdk1wt mice (filled columns).  
*Statistically significant difference between pdk1hm and pdk1wt mice. 
 
In the absence of luminal substrates, the transepithelial potential difference (Vte) of jejunal 
segments amounted to -4.17 ± 0.33 mV (n = 13) in pdk1hm mice and to -4.11 ± 0.24 mV 
(n = 14) in pdk1wt mice. The transepithelial resistance (Rte) approached 9.4 ± 0.7 O · cm2 
(n = 13) in pdk1hm mice and 8.3 ± 0.4 O cm2 (n = 14) in pdk1wt mice. Neither 
transepithelial potential difference nor transepithe lial resistance were significantly 
different between pdk1hm and pdk1wt mice. Accordingly, calculated basal short circuit 
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current (Isc, basal) was also not different between the two genotypes, reaching -472 ± 56 
µA/cm2 in pdk1hm mice and -514 ± 46 µA/cm2 in pdk1wt mice, respectively. 
The iso-osmotic replacement of mannitol by phenylalanine, cysteine, glutamine, proline 
or leucine created a lumen-negative shift of the transepithelial potential difference (? Vaa) 
without significantly altering the transepithelial resistance. The ? Vaa and Rte allowed the 
calculation of the amino acid induced short-circuit current (Isc,aa). The Isc,aa was smaller in 
pdk1hm than in pdk1wt mice, a difference reaching statistical significance for 
phenylalanine, cysteine, glutamine, proline, leucine and tryptophan (Table 3, Fig. 14). The 
currents induced by methionine, valine and citrulline tended to be lower in pdk1hm mice, a 
difference, however, not reaching statistical significance between the genotypes (Table 3, 
Fig. 14).  
Table  3. Amino acid induced currents in jejunum. 
Amino acid Current in pdk1wt Current in pdk1hm  n 
phenylalanine -373 ± 33 -245 ± 44* 13-14 
cysteine -389 ± 47 -243 ± 35* 13-14 
glutamine -447 ± 62 -284 ± 49* 13-14 
proline -367 ± 30 -254 ± 36* 13-14 
leucine -697 ± 57 -423 ± 35* 5 
tryptophan -260 ± 20 -196 ± 19* 6 
methionine -435 ± 44 -334 ± 35 6 
valine -568 ± 90 -462 ± 70 6 
citrulline -478 ± 110 -333 ± 56 6 
Arithmetic means ± SEM of the currents (in µA/cm2) generated by the respective amino acids (20 mM).  
* statistically significant difference between pdk1hm and pdk1wt mice, n = number of mice studied. 
 
Similar to intestine, proximal renal tubules display decreased electrogenic transport of 
amino acids. As illustrated in (Fig. 15), the potential difference across the basolateral cell 
membrane (PDbl) of isolated perfused straight proximal tubules (i.e. late parts of proximal 
tubule) was in the absence of amino acids not significant ly different between pdk1hm 
mice (-51.4 ± 2.5, n = 13) and pdk1wt mice (-54.4 ± 1.5 mV, n = 14). Addition of 20 mM 
L-phenylalanine, L-glutamine or L-proline, respectively, to the luminal fluid significantly 
decreased PDbl in both, pdk1hm and pdk1wt mice, an effect, however, significantly 
smaller in pdk1hm than in pdk1wt mice (Fig. 15). 
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Figure 15. Effect of amino acids on the potential difference across the basolateral cell membrane of 
straight proximal tubules.  
A, B) Original tracings illustrating the effect of the luminal application of 20 mM phenylalanine (Phe), 
glutamine (GLN), and proline (PRO) in the presence of the K channel blocker Ba2+ (1mM) on the potential 
difference across the basolateral cell membrane of straight proximal tubules (PDbl) from PDK1 
hypomorphic mice (pdk1hm) and WT littermates (pdk1wt).  
C) Arithmetic means ±se of the depolarization of the basolateral cell membrane from pdk1hm mice (open 
columns) and pdk1wt mice (filled columns) following the luminal replacement of 20 mM mannitol with 20 
mM phenylalanine (n5 pdk1hm and 6 pdk1wt), glutamine (n5 pdk1hm and 5 pdk1wt) or proline (n3 pdk1hm and 3 
pdk1wt).  
*Statistically significant difference between pdk1hm and pdk1wt mice. 
 
In order to assess the abundance of major amino acid transporter proteins expressed in the 
brush border membrane of the proximal tubule, immunoblotting was performed with 
isolated brush border membranes from kidney. A reduced abundance of the major renal 
Na+-dependent amino acid transporter for neutral amino acids, B0AT1 (SLC6A19), was 
found (Fig. 16).  
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Figure 16. Abundance of amino acid transporters in kidney brush border membrane. A) Immunoblots 
for b0,AT (SLC7A9), SIT (SLC6A20), EAAC1 (SLC1A1), B0AT1 (SLC6A19) amino acid transporters, and 
actin demonstrate the significant reduction in protein abundance of b0,AT, EAAC1, B0AT1, and increased 
expression of SIT amino acid transporters in the renal brush border membrane of pdk1hm mice. 
 B) Bar graphs summarizing quantification of amino acid transporter abundance normalized for loading with 
actin (ratio transporter/actin).  
*Statistically significant differences between pdk1wt (open columns) and pdk1hm (open columns) mice (n5 
for each genotype). 
 
In parallel, the abundance of the Na+-dependent glutamate transporter EAAC1/ EAAT3 
(SLC1A1) was decreased. Also expression of the b0,+AT (SLC7A9) protein, the catalytic 
subunit of system b0,+ responsible for the reabsorption of cationic amino acids and cystine, 
was reduced. The expression of the Na+,proline cotransporter SIT (SLC6A20) was, 
however, enhanced in the pdk1hm kidney. Thus, at least in the kidney, decreased 
expression of several major renal amino acid transporters contributes to the impaired 
amino acid reabsorption in PDK1 hypomorphic mice.  
Further experiments were performed to elucidate the plasma concentrations and renal 
excretion of the amino acids. As evident from Table 4, the plasma concentration of none 
of the amino acids was significantly different between pdk1hm  and pdk1wt mice.  
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Table  4. Plasma concentrations of amino acids in pdk1hmand pdk1wt mice 
 pdk1 wt pdk1 hm 
Glycine 275.4 ± 29.4 279.8 ± 32.7 
Alanine 398.9 ± 64.7 375.7 ± 54.8 
Aminobutyrate 23.2 ± 2.7 18.9 ± 1.6 
Serine 38.7 ± 5.9 34.9 ± 5.4 
Proline 53.2 ± 11.7 66.2 ± 16.1 
Valine 223.2 ± 28.8 269.5 ± 36.5 
Threonine 31.3 ± 6.0 37.3 ± 6.7 
5-Oxoproline 15.9 ± 1.6 16.5 ± 1.3 
Leucine+Isoleucine 216.0 ± 23.7 250.0 ± 32.8 
Asparagine 34.2 ± 4.3 43.3 ± 5.6 
Methionine 71.5 ± 11.1 83.2 ± 11.4 
Histidine 33.9 ± 2.2 32.5 ± 1.7 
Citrulline 53.4 ± 4.3 55.6 ± 4.5 
Phenylalanine 110.8 ± 12.8 118.2 ± 16.7 
Methylhistidine 44.3 ± 2.6 43.6 ± 2.3 
Tyrosine 140.9 ± 21.2 138.2 ± 17.1 
Aspartate 23.7 ±  3.7 24.7 ± 4.5 
Glutamate/Glutamine 71.5 ± 8.1 60.3 ± 8.3 
Tryptophan 20.1 ±  2.2 18.2 ± 2.2 
Aminoadipate 5.1   0.9 6.8 ± 1.3 
N-Acetylasparaginic acid 2.1 ± 0.4 1.6 ± 0.3 
Ornithine 49.2 ± 6.4 70.4 ± 12.8 
Arithmetic means ± SEM (n = 11) of the individual amino acid concentrations in plasma (µM) from PDK1 
hypomorphic (pdk1hm) mice and wild type littermates (pdk1wt). 
 
Table 5 shows the urinary excretion of creatinine and amino acids. The average daily 
urinary creatinine excretion was not significantly different between pdk1hm mice (17.6 ± 
1.2 µg/24h/g BW) and pdk1wt mice (15.7 ± 0.7 µg/24h/g BW). To account for individual 
variations of urinary concentration, the daily urinary excretion of individual amino acids 
was divided by the respective daily creatinine excretion.  
 
Table 5. Urinary excretion of amino acids in pdk1hmand pdk1wt mice. 
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 pdk1 wt pdk1 hm 
Glycine 496.3 ± 86.4 526.5 ± 110.7 
Alanine 143.8 ± 22.9 208.9 ± 110.7 
Proline 17.0 ± 2.7 34.3 ± 10.6 * 
Valine 19.4 ± 2.3 27.5 ± 3.7 * 
Guanidinoacetate 301.7 ± 32.3 414.6 ± 52.0 * 
Leucine 153.5 ± 78.3 140.7 ±  73.2 
Creatine 2286.5 ± 263.4 2476.4 ± 272.6 
Ornithine 5.6 ± 1.4 6.4 ± 1.4 
Lysine 21.3 ± 6.7 15.6 ± 5.0 
Methionine 53.4 ± 8.4 94.1 ± 20.0 * 
Histidine 8.2 ± 1.4 15.3 ± 6.7 
Phenylalanine 11.1 ± 1.3 17.6 ± 2.5 * 
Arginine 8.2 ± 2.3 11.8 ± 2.9 
Citrulline 8.5 ± 1.9 14.2 ± 3.0 * 
Tyrosine 28.9 ± 2.6 45.6 ± 10.7 
Glutamine/glutamate 53.9 ± 7.6 105.3 ± 25.2 * 
Tryptophan 4.4 ± 0.5 6.8 ± 1.5  * 
5-Hydroxytryphtophane 0.4 ± 0.2 0.7 ± 0.2 
Cystine 7.17 ± 1.5 9.1 ± 1.9 
Homocystine 0.20 ± 0.1 0.26 ± 0.1 
 
Arithmetic means ± SEM (n=12-14) of the urinary excretion of individual amino acid excretion (in 
mmol/mol creatinine) from PDK1 deficient (pdk1hm) mice and wild type littermates (pdk1wt). * statistically 
significant difference between pdk1h m and pdk1wt mice 
 
As indicated in Table 5, renal excretions of several amino acids were larger in pdk1hm than 
in pdk1wt mice, differences reaching statistical significance for proline, valine, 
guanidinoacetate, methionine, phenylalanine, citrulline, glutamine/glutamate and 
tryptophan. 
 
 
3.1.4 SGK3-dependent regulation of SGLT1 
As reported previously (57), SGK3 knockout mice (sgk3-/-) gain weight after birth slightly 
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slower than their wild type littermates (sgk3+/+). However, at the age under study (5-7 
months after birth) the weight was virtually identical in sgk3-/- (29.1 ± 0.9 g, n = 10) and 
sgk3+/+ mice (29.4 ± 1.1 g, n = 10). 
As evident from in situ hybridization (Fig. 17), SGK3 was expressed in small intestine. 
 
A
C
B
TM
 
Figure 17. In situ hybridization for SGK-3 mRNA on cryostat sections of the adult jejunum. 
A: Overview of SGK-3 expression in the jejunum. Arrows point to stained crypts of Lieberkuhn; TM: tunica 
muscularis; scale bar 100 µm.  
B: High magnification photomicrograph of SGK -3 expression in the jejunum. Note the expression of 
epithelial cells in the crypts (arrowheads), scale bar: 25 µm.  
C: SGK-3 mRNA in situ hybridization of jejunum from SGK3 -/- mouse. Arrowheads point to the base of 
crypts; scale bar: 25 µm.  
 
Transcript levels were particularly high in crypts but are also detectable in more apical 
regions of the villi.  
Food intake of sgk3-/- mice (4.62 ± 0.15 g/24h, n=10) was significantly (p<0.003) larger 
than food intake of sgk3+/+ mice (3.71 ± 0.23 g/24h, n=10) while drinking volume was not 
significantly different between sgk3-/- mice (6.56 ± 0.32 ml/d, n = 10) and sgk3+/+ mice 
(6.83 ± 0.39 ml/d, n = 10). Fecal weight was significantly (p<0.027) larger in sgk3-/- mice 
(37.80 ± 2.28 mg/g BW/24h, n=10) than in sgk3+/+ mice (28.50 ± 3.12 mg/g BW/24h, 
n=10). The difference in fecal weight was paralleled by significantly (p<0.035) larger 
fecal K+ excretion in sgk3-/- mice (6.99 ± 0.52 µmol/ g BW/24h, n=10) than in sgk3+/+ 
mice (5.42 ± 0.46 µmol/g BW/24h, n=10). Fecal excretion of Na+ and phosphorus (Pi) 
tended to be higher in sgk3-/- than in sgk3+/+ mice (Fig. 18), a difference, however, not 
statistically significant (p= 0.129 and p=0.057 respectively). 
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Figure 18. Food and water intake, fecal weight and fecal sodium, potassium and phosphorus . 
Arithmetic means ± SEM (n = 10 each) of food and water intake, fecal weight (A and B) and fecal sodium, 
potassium and inorganic phosphorus content (C) in sgk3+/+ mice (open columns) and sgk3-/- mice (closed 
columns).* Indicates statistically significant difference (p<0.05) between sgk3+/+ and sgk3-/- mice. 
 
To elucidate the in vivo significance of SGK3-dependent regulation of SGLT1, proximal 
and distal segments of jejunum from sgk3-/- and sgk3+/+ mice were mounted into mini-
Ussing chambers and Na+ coupled glucose transport was determined utilizing 
electrophysiological analysis (Fig. 19).  
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Figure 19. Glucose induced currents (Ig,p) in proximal intestinal segments  
Glucose induced alterations of transepithelial voltages (A) and glucose induced currents (B) in proximal 
segments of jejunal tissue from sgk3-/- and sgk1+/+ mice.  
A: Original tracings illustrating the effect of 20 mM glucose replacing 20 mM mannitol (Man) on the 
transepithelial potential difference in sgk1+/+ mice (upper panel) and sgk3-/- mice (lower panel). The voltage 
deflections are due to repetitive injections of test currents (1 µA). 
B: Arithmetic means ± SEM (n = 15-19) of glucose induced currents in proximal jejunum from sgk3+/+ mice 
(open columns) and sgk3-/- mice (closed columns). 
 
In the absence of luminal substrates, the transepithelial potential difference (Vt,p) of 
proximal intestinal segments amounted to -0.61 ± 0.11 mV (n = 19) in untreated sgk3-/- 
mice and to -0.67 ± 0.12 mV (n = 15) in untreated sgk3+/+ mice. The transepithelial 
resistance (Rt,p) approached 23.75 ± 2.02 O*cm2 (n = 19) in sgk3-/- mice and 24.55 ± 1.86 
O*cm2 (n = 15) in sgk3+/+mice. Neither transepithelial potential difference nor 
transepithelial resistance were significantly different between sgk3-/- and sgk3+/+mice. 
The partial isoosmotic replacement of mannitol by glucose created a lumen-negative shift 
of the transepithelial potential difference (? Vg,p) without significantly altering the 
transepithelial resistance (Fig. 20). In proximal jejunum the glucose induced current (Ig,p) 
at 10, 20 and 40 mmol/l glucose amounted to -23.35 ± 2.69 µA/cm2; -42.65 ± 5.39 
µA/cm2  and -56.16 ± 7.08 µA/cm2 (n=19) in sgk3 -/- mice and to -32.87 ± 5.56 µA/cm2, -
52.71 ± 9.13 µA/cm2 and -76.25 ± 12.02 µA/cm2 (n=15) in sgk3+/+mice. The increase in 
the proximal intestinal transepithelial potential difference following partial isosmotic 
replacement of mannitol by glucose tended to be smaller in sgk3-/- mice than in sgk3+/+ 
mice, a difference, however, not reaching statistical significance (10 mM p =0.139, 20 
mM p= 0.324, 40 mM p= 0.1404). In both genotypes the glucose induced currents did not 
saturate at high glucose concentrations which are well beyond the concentrations required 
for saturating SGLT1 (99;100). Presumably, unstirred layers lead to much lower 
concentrations at the carrier and thus to seemingly low affinity of transport. 
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The transepithelial potential difference (Vt,d) of distal intestinal segments in the absence of 
luminal glucose amounted to -1.00 ± 0.10 mV (n = 27) in untreated sgk3-/- mice and to -
0.82 ± 0.09 mV (n = 27) in untreated sgk3+/+ mice. The transepithelial resistance of distal 
intestinal segments (Rt,d) approached 33.21 ± 2.12 O*cm2 (n = 27) in sgk3-/- mice and 
29.20 ± 1.75 O*cm2 (n = 27) in sgk3+/+mice. (Fig.20). 
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Figure 20.Glucose induced currents (Ig,d) in distal intestinal segments 
Glucose induced alterations of transepithelial voltages (A) and glucose induced currents (B) in distal 
segments of jejunal tissue from SGK3 knockout mice (sgk3-/-) and their wild type littermates (sgk3+/+).  
A: Original tracings illustrating the effect of 20mM glucose replacing 20 mM mannitol (Man) on the 
transepithelial potential difference in sgk1+/+ mice (upper panel) and sgk3-/- mice (lower panel). The voltage 
deflections are due to repetitive injections of test currents (1 µA). 
B: Arithmetic means ± SEM (n = 27) of glucose induced currents in distal jejunum from sgk3+/+ (open 
columns) and sgk3-/- mice (closed columns).  
*Indicates statistically significant difference (p<0.05) between sgk3+/+ and sgk3-/- mice. 
 
The transepithelial resistance of distal intestinal segments (Rt,d) approached 33.21 ± 2.12 
O*cm2 (n = 27) in sgk3-/- mice and 29.20 ± 1.75 O*cm2 (n = 27) in sgk3+/+ mice. 
As in proximal intestinal segments, neither transepithelial potential difference nor 
transepithelial resistance were significantly different between sgk3-/- and sgk3+/+mice. The 
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increase in the distal intestinal Ig,d following partial isoosmotic replacement of mannitol 
by glucose was at all three concentrations  tested significantly smaller in sgk3-/- mice (-
12.58 ± 1.61 µA/cm2 ; -18.96 ± 3.54 µA/cm2 and -26.36 ± 4.71 µA/cm2, n=27) than in 
sgk3+/+ mice (-19.95 ± 2.23 µA/cm2, -31.22 ± 4.72 µA/cm2 and -44.98 ± 4.72 µA/cm2, 
n=27). Moreover, the current in the presence of 40 mmol/l glucose which was sensitive to 
the SGLT1 blocker phloridzin (200 µM) was significantly smaller in sgk3-/- mice (11.55 ± 
1.81 µA/cm2 ) than in sgk3+/+ mice (21.81 ± 2.28 µA/cm2).  
Fasting plasma glucose concentrations were significantly (p < 0.034) lower in sgk3-/- mice 
(4.42 ± 0.28 mmol/l, n = 6) than in sgk3+/+ mice (5.33 mmol/l ± 0.29, n=6). 
To explore whether defective electrogenic glucose transport in sgk3-/- intestine is 
paralleled by a similar impairment of electrogenic amino acid transport, the currents 
induced by phenylalanine, cysteine, glutamine, and proline were determined in intestinal 
segments of sgk3-/- and sgk3+/+ mice. No significant differences were observed between 
sgk3-/- and sgk3+/+ mice in the currents of any of the amino acids tested (Fig. 21). 
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Figure 21. Amino acid induced currents (Iaa,d) in intestinal segments. 
Alterations of transepithelial voltages. (A) and induced currents (B) in segments of jejunal tissue from sgk3-/- 
and sgk3+/+ mice before and after addition of phenylalanine (Phe), cysteine (Cys), glutamine (Glu), and 
proline (Pro). 
A: Original tracings illustrating the effect of amino acids on the transepithelial potential difference in 
sgk1+/+ mice (upper panel) and sgk3-/- mice (lower panel). The voltage deflections are due to repetitive 
injections of test currents (1 µA). 
.B: Arithmetic means ± SEM (n = 6-7) of amino acid induced currents in jejunum from sgk3+/+ mice (open 
columns) and sgk3-/- mice (closed columns).  
 
3.1.5  Quantitative RT-PCR  
We used quantitative RT-PCR to test whether colonic SGK1 transcription is up-regulated 
by a four day treatment with dexamethasone or a seven day treatment with DOCA 
(Fig.22). 
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Figure 22. SGK1 expression 
Arithmetic means ± SEM (n = 3-4 each) of SGK1 mRNA transcript levels in wild-type mice prior to (open 
bars) and following (closed bars) treatment with the mineralocorticoid DOCA or with the glucocorticoid 
dexamethasone (DEX).  
# Indicates statistically significant difference between untreated and treated mice. 
 
Following dexamethasone treatment the mSGK1/mGAPDH ratio increased in distal colon 
from 7.2 ± 0.4 (n = 3) to 69.6 ± 14.0 copies mSGK1/ 103 copies mGAPDH (n = 4). 
Following DOCA treatment the ratio increased in distal colon from 9.1 ± 2.1 (n = 3) to 
95.6 ± 44.4 copies mSGK1/ 103 copies mGAPDH (n = 3). Hence, both, the glucocorticoid 
dexamethasone and the mineralocorticoid DOCA up-regulate SGK1 transcript levels. No 
SGK1 transcripts were detected in SGK1 knockout mice (SGK1/GAPDH ratio 0.0, n=4 in 
distal colon).  
The potential difference across the colonic epithelium was determined to estimate ENaC 
activity. In untreated animals the transepithelial potential difference (Vte) across the 
colonic epithelium was significantly higher in untreated sgk1-/- mice than in untreated 
sgk1+/+ mice ( -6.8 ± 1.1 mV vs. -3.9± 0.5 mV, n=12-14 each).  
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Figure 23. Amiloride-sensitive transepithelial potential in distal colon 
A. Representative original tracings of the transepithelial colonic potential difference (Vte) in sgk1
+/+ mice 
and sgk1-/- mice under control diet (left) and low salt diet (right) before and after addition of 50µM 
amiloride (open arrow). 
B: Arithmetic means ± SEM (n = 4-14) of transepithelial potential difference (Vte) across distal colonic 
epithelium in the absence and presence (+Amil) of amiloride (50 µM) in sgk1+/+ mice (open bars) and sgk1-/- 
mice (closed bars) under control diet, low salt diet, treatment with the mineralocorticoid DOCA (1.5mg per 
day) or treatment with the glucocorticoid dexamethasone (DEX, 10µg/g BW ). 
# indicates statistically significant difference between control and the respective treatment,  
* indicates statistically significant difference between sgk1+/+ and sgk1-/- mice. 
 
As shown in Fig. 23, addition of the Na+ channel blocker amiloride (50 µM) decreased Vte 
to +0.1 ± 0.4 mV in sgk1-/- mice (n=14) and to -0.5 ± 0.4 mV in sgk1+/+ mice (n=12). The 
lumen positive Vte in the presence of amiloride was not significantly different from zero 
and thus, Vte was fully dependend on amiloride sensitive ENaC activity. Vte and apparent 
Rte allowed the calculation of an apparent amiloride-sensitive equivalent short circuit 
current (Iamil) in distal colon. As illustrated in Fig.24 Iamil was significantly larger in 
untreated sgk1-/- mice (-595 ± 135 µA/cm2, n=12) than in untreated sgk1+/+ mice (-231 ± 
33µA/cm², n=14).  
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Figure 24. Amiloride-sensitive current in distal colon 
Arithmetic means ± SEM (n = 4-14) of the amiloride-sensitive equivalent short circuit current (Iamil) in distal 
colon from sgk1+/+ mice (open columns) and sgk1-/- mice (closed columns) under control diet, low salt diet, 
treatment with the mineralocorticoid DOCA (1.5mg per day) or treatment with the glucocorticoid 
dexamethasone (DEX, 10µg/g BW).  
# indicates statistically significant difference between control and the respective treatment,  
* indicates statistically significant difference between sgk1+/+ and sgk1-/- mice. 
 
The next series of experiments explored the influence of salt deficient diet, a maneuver 
increasing aldosterone release and thus increasing endogeneous mineralocorticoid 
stimulation of ENaC. A 7 day treatment with low salt diet significantly decreased body 
weight despite significant stimulation of fluid intake in both genotypes (Table 6). 
 
Table  6. Arithmetic means ± SEM of the effects of 3 mM luminal Ba2+ 
Control diet (n=9 
each) 
Low salt diet (n=4 
each) 
DEX (n=8 each) DOC (n=5 each) 
 
sgk1+/+ sgk1-/- sgk1+/+ sgk1-/- sgk1+/+ sgk1-/- sgk1+/+ sgk1-/- 
? Vte
, mV 
-0.88  
±   
0.13 
-0.50  
±  
0.13* 
-0.32  
±  
0.07# 
-0.64 
± 
0.11# 
-0.46  
±  
0.09# 
-1.00 
± 
0.03# *  
-0.88 
±   
0.09 
-0.88   
±  
0.12# 
 
Arithmetic means ± SEM of the effects of 3 mM luminal Ba2+ on Vte in the presence of amiloride under 
control and low salt diet as well as after dexamethasone (DEX) and DOCA (DOC) treatment. 
#indicates significant difference between control and respective treatment.  
*indicates statistically significant difference between sgk1+/+ and sgk1-/- mice 
 
Salt deficient diet increased the absolute value of Vte and Iamil in both, sgk1-/- and sgk1+/+ 
mice (Fig. 22 and 24, n=4 each). Under low salt diet Vte and Iamil remained significantly 
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higher in sgk1-/- than in sgk1+/+ mice. Thus, lack of SGK1 does not blunt the effect of salt 
depletion on colonic transepithelial potential difference. 
To elucidate the cause for the higher Vte and Iamil in sgk1-/- mice under control conditions 
and low salt diet we examined plasma aldosterone levels in both genotypes (Fig. 25).  
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Figure 25. Plasma aldosterone concentrations 
Arithmetic means ± SEM of plasma aldosterone concentrations in sgk1-/- (closed columns) and sgk1+/+ mice 
(open columns, n = 12 each) under control diet (left) and low salt diet (right). # indicates statistically 
significant difference between diets,  
* Indicates statistically significant difference between sgk1+/+ and sgk1-/- mice. 
 
Aldosterone plasma levels were significantly higher in sgk1-/- mice (1.2 ± 0.3 ng/ml, 
n=12) than in sgk1+/+ mice (0.5 ± 0.2 ng/ml, n=12). Under low salt diet plasma 
aldosterone levels were strongly enhanced in both genotypes and remained significantly 
higher in the sgk1-/- mice (18.7 ± 3.3 ng/ml, n = 12) than in in sgk1+/+ mice (9.6 ± 0.3 
ng/ml, n=12).  
Additional experiments have been performed to explore whether the up-regulation of 
SGK1 by the glucocorticoid dexamethasone (n=7-8 each) or the mineralocorticoid DOCA 
(n=7-8 each) participates in the regulation of the potential difference across the colonic 
epithelium. A 4 day dexamethasone treatment (10µg/g BW) significantly increased Vte 
and Iamil in sgk1+/+ mice (Fig. 24). In sgk1-/- mice Vte tended to increase as well, an effect, 
however, not reaching statistical significance. Thus, following dexamethasone treatment 
Vte and Iamil were not significantly different between sgk1-/- than sgk1+/+ mice. Similarly, a 
7 day treatment with DOCA (1.5mg/day ) significantly increased Vte and Iamil in sgk1+/+ 
mice (Fig. 24). 
In sgk1-/- mice Vte tended to increase as well, an effect, however, again not reaching 
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statistical significance (p=0.07). Thus, the increase of transepithelial potential difference 
following glucocorticoid or mineralocorticoid treatment is blunted in sgk1-/- mice. 
To assess the contribution of K+ channels to measured Vte, Ba2+ was added to the luminal 
perfusate in the presence of amiloride. As shown in Table 6, Ba2+ had only little effect on 
Vte suggesting that most of the Vte reflected amiloride-sensitive ENaC activity.  
For the analysis of the fecal Na+ and K+ excretion feces was collected over 24 h with free 
access to control diet and distilled drinking water (Table 7). 
Table 7.Arithmetic means ± SEM of body weight, food and fluid intake 
Control diet Low salt diet  
sgk1+/+ sgk1-/- sgk1+/+ sgk1-/- 
Body Weight (g) 26.0 ± 1.3  25.4 ± 1.4 23.7 ± 1.2 # 22.5 ± 1.2 # 
Food intake (g/24h ) 3.2 ± 0.2 3.0 ± 0.1 2.5 ± 0.2 # 2.2 ± 0.2 # 
Fluid Intake (ml/24h) 3.8 ± 0.4 3.3 ± 0.2 8.9 ± 1.8 # 8.6 ± 1.0 # 
Calculated Na+ intake 
(µmol/24h) 
379 ± 26 356 ± 16 18.3 ± 1.3 # 16.3 ±1.1 # 
Fecal Na+ excretion / Na+ 
intake (%) 
13.3 ± 1.4 12.8 ± 1.0 191 ± 20 # 179 ± 25 # 
Fecal Na+ excretion 
(µmol/24h) 
48.4 ± 4.7 44.6 ± 3.2 33.9 ± 3.4 # 29.9 ± 4.9 # 
Calculated K+ intake 
(µmol/24h) 
2022 ± 139 1900 ± 83 1607 ± 117 # 1427 ± 97 # 
Fecal K+ excretion 
(µmol/24h) 
37.0 ± 4.0 42.5 ± 6.5 62.6 ± 5.3 # 45.5 ± 3.8 
Fecal K+ excretion / K+ 
intake (%) 
1.87 ± 0.18 2.21± 0.27 4.02 ± 0.37 # 3.22 ± 0.20 # 
 
Arithmetic means ± SEM of body weight, food and fluid intake, calculated Na+ and K+ intake, fecal weight 
as well as fecal Na+ and K+ excretion in sgk1+/+ and sgk1-/- mice treated with control diet or salt depleted diet 
and distilled water for 5 days (n = 12 each). 
# indicates significant difference between control and low salt diet. 
 
Under control conditions fecal Na+ excretion was similar in sgk1+/+ mice (48.4 ± 4.7 
µmol/24h, n=12) and in sgk1-/- mice (44.6 ± 3.2 µmol/24h, n=12). Under low Na+ diet 
fecal Na+ excretion was similarly decreased in sgk1+/+ (33.9±3.4 µmol/24h, n=12) and 
sgk1-/- mice (29.9±4.9 µmol/24h, n=12, Fig. 26). 
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Figure 26. Fecal Na+ excretion  
Arithmetic means ± SEM (n = 12 each) of fecal Na+ excretion in sgk1+/+ mice (open columns) and sgk1-/- 
mice (closed columns) under control diet (left) and low salt diet (right). # indicates statistically significant 
difference between control and low salt diet. 
 
Fecal K+ excretion was similarly increased in both genotypes. A 4 day treatment with 
dexamethasone decreased fecal Na+ excretion in both sgk1+/+ and sgk1-/- mice without 
increasing fecal K+ excretion (Table8). 
 
 
Table  8.Arithmetic means ± SEM of body weight, food and fluid intake, calculated Na+ and K+ intake 
Control DEX treatment  
sgk1+/+ sgk1-/- sgk1+/+ sgk1-/- 
Body Weight (g) 27.4 ± 1.3  28.0 ± 1.1 26.7 ± 1.2  27.4 ± 1.1  
Food intake (g/24h) 3.3 ± 0.2 3.7 ± 0.1 4.0 ± 0.2 # 4.2 ± 0.2 # 
Fluid Intake (ml/24h) 5.3 ± 0.4  6.1 ± 0.4 7.4 ± 1.0 # 6.9 ± 0.5 # 
Calculated Na+ intake (µmol/24h) 397 ± 19 437 ± 14 485 ± 18 # 501 ± 19 # 
Fecal Na+ excretion (µmol/24h) 87.0 ± 11.3  78.0 ± 9.0  40.3 ± 4.9 # 44.4 ± 4.0 # 
Fecal Na+ excretion / Na+ intake (%) 22.2 ± 2.9 17.9 ± 2.1 8.5 ± 1.1 # 8.9 ± 0.7 # 
Calculated K+ intake (µmol/24h) 2119 ± 100  2334 ± 72 2586 ± 95 # 2673 ± 101 # 
Fecal K+ excretion (µmol/24h) 155 ± 19 157 ± 15 141 ± 14 146 ± 13 
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Fecal K+ excretion / K+ intake (%) 7.5 ± 0.9 6.8 ± 0.8 5.5 ± 0.5 # 5.5 ± 0.5 
 
Arithmetic means ± SEM of body weight, food and fluid intake, calculated Na+ and K+ intake, fecal weight 
as well as fecal Na+ and K+ excretion in sgk1+/+ and sgk1-/- mice treated with control diet and dexamethasone 
(DEX) for 4 days (n = 12 each). 
# indicates significant difference between control and dexamethasone treatment. 
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4 Discussion 
4.1 Effect of PI3 kinase inhibitors on electrogenic transepithelial 
transport of glucose 
The present observations disclose the powerful influence of PI3 kinase inhibitors on 
electrogenic transepithelial transport of glucose and several amino acids.  
Notably, the effect of PI3 kinase inhibitors occurs in the absence of any exogeneous 
hormonal stimulation of the tissue, such as IGF, further growth factors, insulin or 
glucocorticoids. Apparently, activation of the PI3 kinase is at least transiently maintained 
even in the absence of continued hormonal stimulation. Thus, the hormonal effect is 
maintained transiently even without continued presence of those hormones or PI3 kinase 
is activated by some other intramural mechanisms. Accordingly, PI3 kinase may not only 
be important for the stimulation of intestinal transport by hormones but may be required 
for the maintenance of transport even in the absence of hormones. Unlike glucose- induced 
currents, amino acid and forskolin- induced currents decreased substantially even in the 
absence of Wortmannin, which may point to relaxation of the effect or transport 
dependence on continuous exogenous stimulation. However forskolin and amino acid 
induced currents declined significantly faster in the presence of Wortmannin.  
The present experiments did not address the mechanisms underlying the inhibition of 
electrogenic transport. Previous in vitro studies revealed the stimulating effect of the SGK 
isoforms and/or PKB on the electrogenic glucose transporter SGLT1 (13), the glutamine 
transporter SN1 (SLC38a3, SNAT3) (101) and the glutamate transporters EAAT1, (17), 
EAAT2 (18), EAAT3 (19), EAAT4 (20) and EAAT5 (21). Most likely, further amino acid 
transporters are targets of the SGK and PKB isoforms and thus dependent on PI3 kinase 
activity. Moreover, the kinases stimulate the voltage gated K+ channel complex 
KCNE1/KCNQ1 (102). The channels contribute to the maintenance of the potential 
difference across the apical cell membrane (88;92) which is a critical driving force for 
electrogenic glucose and amino acid transport (44;103;104). The SGK isoforms have 
further been shown to stimulate the Na+/K+-ATPase (105-107), which is required for the 
maintenance of the Na+ gradient, the second driving force for Na+ coupled nutrient 
transport (104). 
Inhibition of PI3- kinase may similarly affect the transport of electrolytes such as CFTR 
(108) or ClC-Ka/barttin (109)dependent Cl- transport, ROMK dependent K+ transport 
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(110-112), TRPV5 dependent Ca2+ transport (113;114)or Na+ through the epithelial Na+ 
channel ENaC, The latter is is regulated by insulin, and IGF-1 through the PI3 kinase 
pathway (62;63;115). ENaC is regulated by SGK1 (58;59), complete knockout of SGK1 
leads, however, only to moderate impairment of renal Na+ retention (64). 
At least in theory, the decline of transport in the presence of Wortmannin could have been 
due to unspecific epithelial injury. However, the transepithelial resistance was not 
significantly affected by the presence of Wortmannin or LY294002. Moreover, TUNEL 
staining did not reveal evidence for apoptosis following a 15 minute treatment with 
Wortmannin. Nevertheless, we cannot rule out tissue damage by the PI3 kinase inhibitors 
which may eventually contribute to a decline of transport activity. 
In conclusion, pharmacological inhibition of PI3 kinase markedly decreases the 
electrogenic transport of glucose and several amino acids. Thus, the PI3 kinase pathway is 
required to maintain intestinal transport function. 
 
4.2 Intestinal and renal glucose transport 
According to the Ussing chamber experiments and electrophysiology of proximal renal 
tubules, electrogenic glucose transport is significantly smaller in PDK1 hypomorphic 
mice (pdk1hm) than in their wild type littermates (pdk1wt). PDK1 could regulate SGLT1 
through the downstream kinases PKB and SGK, which have previously been shown to 
stimulate the electrogenic glucose transporter SGLT1 expressed in Xenopus oocytes (13). 
Moreover, these kinases also stimulate the voltage gated K+ channel complex 
KCNE1/KCNQ1 (109), which contributes to the maintenance of the potential difference 
across the apical cell membrane of the renal proximal tubule (92), a critical driving force 
for electrogenic glucose transport  (44;103). K+ channels similarly maintain the driving 
force of intestinal glucose transport (104). The kinases further stimulate the Na+/K+-
ATPase (105;106), which is required to maintain the chemical driving force for Na+ 
coupled nutrient transport (44;103;104). Thus, PDK1 may regulate SGLT1 activity both 
directly and by modifying the respective driving forces.  
Decreased expression of PDK1 in the PDK1 hypomorphic mice does not only affect 
glucose transport but may affect a variety of other transport systems dependent on the 
SGK and PKB isoforms (7). Again, those transport systems may be affected by a direct 
regulation and/or by modification of the driving forces.  
Deranged transport may contribute to the smaller size of the PDK1 hypomorphic mice 
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reported earlier (41). Interestingly, the animals excrete slightly less creatinine (see Table 
2) pointing to some decrease of creatinine formation. Recent experiments have disclosed 
the ability of SGK isoforms to stimulate the creatine transporter (116). As formation of 
creatinine requires the cellular uptake of creatine (117), impaired function of the creatine 
transporter is expected to decrease the formation and renal excretion of creatinine. The 
increased ratio of glucose over creatinine concentration in urine is, however, largely due 
to marked glucosuria rather than slightly decreased creatinine excretion.  
The protein abundance of SGLT1 in the brush border membrane of the jejunum, ileum 
and kidney was not significantly different between pdk1hm mice and pdk1wt mice. The 
scatter of the data does, however, not preclude effects of PDK1 on SGLT1 expression. 
Moreover, the residual PDK1 activity in the hypomorphic mice may be sufficient to 
maintain expression. Irrespective of the underlying mechanism, the observations disclose 
that SGLT1 activity in the brush border membrane is regulated by PDK1. The ß-
adrenergic regulation of glucose transport in rat small intestine has previously been shown 
to involve phosphorylation dependent SGLT1 stimulation (118), whereas IGF mediated 
stimulation of intestinal glucose transport via SGLT1 has been reported to involve 
increase of mRNA and protein abundance (119).The effect of PDK1 deficiency is only 
moderate, but could be more profound at complete knockout of PDK1. Complete 
knockout of SGK3 leads to a moderate decrease of intestinal SGLT1 activity (120). 
Complete knockout of SGK1 abrogates the SGLT1-stimulating effect of dexamethasone 
without appreciably affecting the basal activity of SGLT1 (94). The defective intestinal 
and renal glucose transport did not appreciably alter basal plasma glucose concentration. 
The increase of plasma glucose concentration following intraperitoneal glucose 
administration tended to be slightly higher in pdk1hm mice than in pdk1wt mice. The 
difference, however, did not reach statistical significance. Thus, the ability of 
nonpolarized cells such as muscle or liver to accumulate glucose following an increase of 
plasma glucose concentration is not severely affected in the PDK1 hypomorphic mouse. 
This observation may be surprising in view of the substantial role of PKB (121-127) and 
SGK1 (128) in peripheral glucose uptake. Again, it should be kept in mind that the 
hyopomorphic mice do not completely lack PDK1, which would not be compatible with 
survival. Thus, the residual PDK1 activity may be able to maintain almost normal glucose 
uptake into peripheral tissues but may not be sufficient for full stimulation of intestinal 
and renal glucose transport. 
In conclusion, the PDK1 hypomorphic mice display moderate impairment of electrogenic 
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epithelial glucose transport, an observation disclosing a novel player in the regulation of 
intestinal and renal nutrient transport. 
In conclusion, the PDK-1 hypomorphic mice display moderate impairment of electrogenic 
epithelial glucose transport, an observation disclosing a novel player in the regulation of 
intestinal and renal nutrient transport. 
 
4.3 Intestinal and renal transport of amino acids 
As reported previously (41), PDK1 hypomorphic mice (pdk1hm) are significantly smaller 
than their age and sex matched wild type littermates (pdk1wt). Evidence suggested that the 
decrease of body mass is the result of smaller cell volumes and not due to a decrease in 
cell number (41). In theory, a decrease of cell volume could be due to lack of nutrients, as 
concentrative uptake of amino acids leads to cell swelling and subsequent stimulation of 
protein synthesis (42;43;129). Accordingly, the decreased cell volume could be due to 
impaired nutrient uptake.  
Moreover, insufficient dietary supply or defective renal or intestinal uptake of amino acids 
is typically paralleled by delayed growth (130-134). Thus, the impaired intestinal uptake 
and renal retention of amino acids could contribute to the growth defect of the PDK1 
deficient mice. On the other hand, food and water intake was not decreased in PDK1 
deficient mice, further highlighting the significance of impaired intestinal absorption.  
According to the Ussing chamber experiments, electrogenic transport of phenylalanine, 
cysteine, glutamine, proline, leucine and tryptophan is impaired. Previous in vitro studies 
revealed the stimulating effect of the SGK isoforms and/or PKB on the amino acid 
transporters SN1 (SLC38A3, SNAT3) (20), ASCT2 (SLC1A5) (135), EAAT1 (SLC1A3) 
(18), EAAT2 (SLC1A2) (21), EAAT3 (SLC1A1) (19), EAAT4 (SLC1A6) (17) and 
EAAT5 (SLC1A7) (101). Possibly, other transporters may also be targets of these kinases. 
The profile of amino acids in urine and the observed reduction in transport induced 
currents for several amino acids point to the involvement of more than one amino acid 
transport system (45). Patients with mutations in either B0AT1 (SLC6A19) or in b0,+AT 
(SLC7A9) and rBAT (SLC3A1) suffer from Hartnup disorder or cystinuria. Both diseases 
are characterized by the impaired renal and intestinal transport of neutral amino acids such 
as phenylalanine and leucine or cationic amino acids and cystine, respectively (51;136-
138). Accordingly, the observed reduction in B0AT1 (SLC6A19) expression correlates 
with the loss of leucine, phenylalanine and glutamine. Na-dependent leucine absorption 
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occurs in the kidney via several systems, including the low affinity system B0 (B0AT1, 
SLC6A19) in the initial part of the proximal tubule and probably related but unidentified 
members of the same gene family. XT2 (SLC6A18) and XT3, two related orphan 
transporters with no clearly established transport function (50) have been observed in the 
late proximal tubule. The electrophysiological measurements in the late proximal tubule 
indicated that amino acid induced currents were smaller in the pdk1hm mice suggesting 
that not only reduction of B0AT1 (SLC6A19) expression in the initial proximal tubule but 
also reduced function (and/or expression) of these putative amino acid transporters may 
contribute to the observed aminoaciduria and reduced currents. The relatively high urinary 
loss of methionine and valine may result from the fact that no compensatory mechanisms 
exist. In contrast, the increased abundance of the SIT transporter may point to a 
compensatory mechanism. SIT (SLC6A20) is mainly expressed in the late proximal 
tubule, appears to transport particularly imino amino acids, and belongs to the same SLC6 
family of amino acid transporters as B0AT1 (SLC6A19) (48-50). Surprisingly, reduced 
abundance of the b0,+AT (SLC7A9) subunit of system b0,+ did not induce urinary loss of 
its typical substrates arginine, lysine, and cystine. Again, the observed decrease in protein 
abundance may not adequately mirror the actual activity in the brush border membrane. 
Other transport systems that may compensate for loss of b0,+ activity are presently not 
known. The increased abundance of SIT may indicate that regulation of amino acid 
transporters by PDK1 does not affect all amino acid transporters. 
The SGK isoforms stimulate the vo ltage gated K+ channel complex KCNE1/KCNQ1 
(109), which contributes to the maintenance of the potential difference across the apical 
cell membrane of the renal proximal tubule (88;92), a critical driving force for 
electrogenic amino acid transport (44;103). K+ channels similarly tune intestinal transport 
of amino acids (104). The SGK isoforms further stimulate the Na+/K+-ATPase (105-
107;139), which is required to maintain the chemical driving force for Na+ coupled 
nutrient transport (104). Thus, decreased PDK1 activity could modify nutrient transport 
indirectly, i,e by compromising the driving forces. The potential difference across the 
basolateral cell membrane of proximal renal tubules was, however, not significantly 
different between pdk1hm and pdk1wt mice. Moreover, a decreased K+ channel activity 
should enhance and not decrease the depolarization following addition of substrates for 
Na+ coupled transport. Thus, the blunted depolarisation in pdk1hm mice reflects decreased 
electrogenic amino acid transport rather than decreased K+ channel activity. 
PDK1 may not only stimulate the transport of amino acids, but may participate in the 
IV                                                                                                                           Discussion 
64 
regulation of further nutrients. SGK1 has been shown to stimulate the activity of the Na+-
glucose cotransporter SGLT1 (SLC5A1) (13) and the facilitative glucose transporter 
GLUT1 (SLC2A1) (140). It has further been shown to stimulate the Na+,dicarboxylate 
cotransporter NaDC-1 (SLC13A2) (141), and the creatine transporter CreaT (SLC6A8) 
(116). 
Any impairment of renal electrolyte excretion by blunted stimulation through PDK1 may 
be compensated by enhanced stimulation through other mechanisms. As a matter of fact, 
despite the powerful stimulating effect of SGK1 on the renal epithelial Na+ channel EnaC 
(58;59), complete knockout of SGK1 leads only to moderate impairment of renal Na+ 
retention which is only disclosed following exposure to a salt deficient diet (64).  
The mild reduction in transport rates observed here may be explained by the only 
moderate decrease of transport function as compared to the loss of function mutations or 
knockout leading to severe loss of the respective amino acids (51;136-138;142). It should 
be kept in mind that the mice still express PDK1 and thus, PDK1 dependent regulation of 
amino acid transport is not completely disrupted in those mice.  
The defective intestinal and renal transport of amino acids did not lead to gross alterations 
of plasma amino acid concentrations. Apparently, the enhanced food intake per body 
weight compensates for the renal loss of amino acids and maintains extracellular amino 
acid concentrations sufficient for cellular uptake. However, the availability of amino acids 
in extracellular fluid does not preclude impairment of cellular amino acid uptake in PDK1 
deficient animals through modification of amino acid transport in nonpolarized cells. 
In conclusion, the PDK1 hypomorphic mice display moderate impairment of amino acid 
transport which presumably contributes to the delayed growth of those mice. Therefore 
the present observations disclose a novel player in the regulation of intestinal and renal 
nutrient transport. 
 
4.4 Role of Sgk 3 gene knock-outon glucose transport 
The impaired intestinal absorption in the SGK3 knockout mouse may account for the 
enhanced fecal weight reflecting increased amounts of food escaping intestinal absorption. 
Considering the many transport systems apparently regulated by the SGK´s (15), several 
transport systems may be downregulated in the SGK3 knockout mouse. However, we 
found evidence only for impaired electrogenic glucose absorption while the transport of 
several amino acids appeared to be normal. This does, not of course, rule out the 
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impairment of further transport systems. The impaired intestinal absorption of glucose 
may account for the observed hypoglycaemia which in turn could stimulate food intake, 
which is significantly increased in the sgk3-/- mouse. The enhanced food intake 
contributes to the increase of fecal dry weight and would tend to compensate for the 
abnormal glucose absorption. 
In any case, the present observations disclose the impaired ability of sgk3-/- mice to absorb 
glucose echoing the ability of SGK3 to up-regulate SGLT1 in the Xenopus oocyte 
expression system (13). Beyond impaired electrogenic glucose transport, the sgk3-/- mice 
excrete more K+ potassium, which may point to some impairment of electrolyte 
absorption. On the other hand, the relative increase of K+ excretion was similar to the 
relative increase of food intake and may thus simply be due to altered load.  
The defect of Na+ glucose cotransport in the SGK3 knockout mouse is only moderate 
indicating that functional expression of SGLT1 does not require the presence of SGK3. 
The activity of SGK3 could be partially replaced by SGK1 or the related protein kinase B 
which both have been shown to up-regulate SGLT1 activity (13). Protein kinase B has 
previously been shown to enhance the abundance of glucose transporters in the cell 
membrane (143-145). It is noteworthy that the in vivo functions of SGK1 and SGK3 may 
only partially overlap. 
The different kinases do, however, not necessarily serve identical functions and the 
phenotypes of the SKG1 and SGK3 knockout mice display striking differences. The 
SGK3 mouse shows transient growth retardation and deranged hair growth but seemingly 
normal renal salt retention (57), while the SGK1 knockout mouse has seemingly normal 
growth and hair but suffers from reduced ability to maintain salt balance under dietary salt 
restriction (64). Unlike transcription of SGK3, the transcription of SGK1 is strongly 
regulated by a variety of hormones (4) including glucocorticoids (2;54;55), 
mineralocorticoids (58-60), gonadotropins (146-149), and TGFß (68;150). Moreover, 
SGK1 transcription is stimulated by cell shrinkage (61). Despite those differences, there is 
considerable overlap of regulation and function. Most importantly, all three SGK isoforms 
and protein kinase B require activation by insulin and growth factors including IGF1 (4). 
Thus, the kinases may participate in the known stimulating effect of insulin like growth 
factor on intestinal nutrient uptake (119;151;152). 
In conclusion, SGK3 is expressed in enterocytes and is a modulator of intestinal glucose 
absorption. The slight impairment of intestinal glucose absorption may contribute to the 
delayed growth of mice lacking functional SGK3 
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4.5 Mineralocorticoids and glucocorticoids enhance the SGK1 transcript 
levels in distal colon 
The present observations demonstrate that mineralocorticoids and glucocorticoids enhance 
the SGK1 transcript levels in distal colon, confirming and expanding earlier observations 
that SGK1 mRNA levels are increased by mineralocortioid treatment (62;72;81). 
However, lack of SGK1 does not decrease the transepithelial potential in the colonic 
epithelium and does not disrupt its increase following salt depletion. The transepithelial 
potential is even higher in gene-targeted mice lacking functional SGK1 (sgk1-/-) than in 
their wild type littermates (sgk1+/+) under both, normal and low salt diet. The increased 
transepithelial potential difference under low salt diet may partially result from 
stimulation of ENaC activity by steroid hormones. The particularly high values especially 
in sgk1-/- mice under salt deficient diet may, however, point to the involvement of 
additional mechanisms.  
Treatment with the glucocorticoid dexamethasone or with the mineralocorticoid DOCA 
significantly enhanced the transepithelial potential difference only in the sgk1+/+ mice 
which under the steroid treatment reached the values of the sgk1-/- mice. At first glance the 
blunted effect of steroid hormones on transepithelial potential in sgk1-/- mice could be 
taken as evidence for SGK1 sensitive stimulation of ENaC activity by steroid hormones. 
On the other hand, even under steroid treatment, the amiloride sensitive transepithelial 
potential difference is not higher in sgk1+/+ mice than in sgk1-/- mice. Thus, it appears that 
due to enhanced plasma aldosterone concentrations in the untreated sgk1-/- mice the effect 
of steroid treatment may be limited in those mice.  
The increased transepithelial potential difference in sgk1-/- mice may at least partially 
result from the increased plasma aldosterone concentrations in those mice. As reported 
earlier (61), the impaired renal ENaC activity leads to a moderate extracellular volume 
contraction in sgk1-/- mice, which in turn increases aldosterone release. The enhanced 
mineralocorticoid action partially compensates for the lack of renal ENaC activity leading 
to virtually normal renal salt excretion (61). The functional significance of SGK1 is 
unmasked by salt depletion which decreases renal salt elimination less rigorously in sgk1-/- 
mice than in sgk1+/+ mice (61). In theory, expression of apical K+ channels could partially 
short circuit the current generated by ENaC activity. If the expression of those putative K+ 
channels were sensitive to SGK1, then lack of SGK1 would reduce the short circuiting 
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and thus increase the transepithelial potential difference. The transepithelial potential 
difference would remain fully amiloride sensitive, as following inhibition of the apical 
Na+ channels with amiloride would hyperpolarize the apical membrane, thus dissipating 
the electrochemical gradient for K+ flux through the K+ channels. Thus, similar to the 
current through ENaC, the short circuiting K+ current would disappear following 
inhibition of ENaC with amiloride. SGK1 stimulates the activity of a number of K+ 
channels, including ROMK1 (55;59;77;153) KCNE1/KCNQ1 (58) Kv1.3 (74;94;154), 
Kv1.5 (155) and Kv4.3 (156). There is little doubt that further K+ channels are under the 
control of SGK1. However, luminal application of the unspecific K+ channel blocker 
barium had only little influence on the colonic transepithelial potential difference and at 
least under control conditions fecal K+ excretion was not decreased in sgk1-/- mice. Thus, 
available experimental evidence does not point to a major contribution of SGK1-sensitive 
K+ channels to the colonic transepithelial potential difference. Nevertheless, the present 
experiments do not rule out the possibility that SGK1 regulates K+ channels in colonic 
epithelium. 
The enhanced amiloride sensitive transepithelial potential difference in the sgk1-/- mice 
contrasts the expectation, that lack of SGK1 should compromize the stimulation of ENaC. 
The observation is at seeming variance to the powerful stimulating effect of SGK1 on 
ENaC in Xenopus oocytes (62;65;73;75;110;157), in cortical collecting duct cells (28;69) 
and in A6 cells (73;74;158). Those in vitro experiments parallel the SGK1 dependent 
regulation of ENaC in the renal collecting duct, where ENaC activity is indeed 
significantly decreased in sgk1-/- mice (61). Moreover, those in vitro experiments 
predicted a role of SGK1 in blood pressure regulation (67) and cardiac action potential 
(82), a prediction impressively confirmed by genetic studies (67;82). Thus, in vitro 
experiments are useful tools to disclose the potential of a signalling molecule to regulate 
channels or transporters but require animal experiments or investigations in humans to 
verify, where and under which conditions the observed regulations do occur in vivo.  
In conclusion, gene-targeted mice lacking SGK1 exhibit higher ENaC activity under 
control and low salt conditions than their wild type littermates, a differene presumably due 
to higher aldosterone levels in the SGK1 knockout animals. Lack of SGK1 does not 
disrupt colonic ENaC activity and its regulation by salt depletion. 
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5 Summary 
The phosphoinositide dependent kinase PDK1 activates the SGK isoforms SGK1, SGK2 
and SGK3 and protein kinase B isoforms which in turn are known to stimulate a variety of 
sodium coupled transporters, such as the renal and intestinal Na+-dependent glucose 
transporter SGLT1. SGK1 is known to be up-regulated by mineralocorticoids and to 
enhance ENaC activity in several expression systems. Moreover, the amiloride-sensitive 
transepithelial potential difference in collecting duct is lower in gene-targeted mice 
lacking SGK1 (sgk1-/-) than in their wild type littermates (sgk1+/+). Accordingly, the 
ability of sgk1-/- mice to decrease urinary sodium output during salt depletion is impaired. 
ENaC activity and thus transepithelial potential difference in the colon are similarly 
influenced by mineralocorticoids.  
The first aim of the present study was to explore the role of PDK1 in in electrogenic 
glucose and amino-acid transport in small intestine and proximal renal tubules As mice 
completely lacking functional PDK1 are not viable, mice expressing 10-25% of PDK1 
(pdk1hm) were compared to their wild type littermates (pdk1wt). Body weight was 
significantly smaller in pdk1hm than in pdk1wt mice. Despite lower body weight of pdk1hm 
mice, food and water intake were similar in pdk1hm and pdk1wt mice.  
Ussing chamber experiments showed that electrogenic transport of glucose as well as 
phenylalanine, cysteine, glutamine, proline, leucine and tryptophan was significantly 
smaller in jejunum of pdk1hm mice compared to pdk1wt mice. Similarly, proximal tubular 
electrogenic glucose transport as well as phenylalanine, glutamine and proline transport in 
isolated perfused renal tubule segments was decreased. Intraperitoneal injection of 3 g/kg 
bw glucose resulted in a similar increase of plasma glucose concentration in pdk1hm and in 
pdk1wt mice but led to a higher increase of urinary glucose excretion in pdk1hm mice. The 
urinary excretion of proline, valine, guanidinoacetate, methionine, phenylalanine, 
citrulline, glutamine/glutamate and tryptophan was significantly larger in pdk1hm than in 
pdk1wt mice. According to immunoblotting of brush border membrane proteins prepared 
from kidney, expression of the Na+-dependent neutral amino acid transporter B0AT1 
(SLC6A19), the glutamate transporter EAAC1/EAAT3 (SLC1A1) and the transporter for 
cationic amino acids and cystine b0,+AT (SLC7A9) was decreased but the Na+/proline 
cotransporter SIT (SLC6A20) was increased in pdk1hm mice. In conclusion, reduction of 
functional PDK1 leads to impairment of intestinal absorption and renal reabsorption of 
amino acids of electrogenic intestinal glucose absorption and renal glucose reabsorption. 
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The combined intestinal and renal loss of amino acids may contribute to the growth defect 
of PDK1 deficient mice. The experiments disclose a novel element of glucose transport 
regulation in kidney and small intestine.  
The next step was to look at the transepithelial potential (Vte) and the apparent amiloride-
sensitive equivalent short circuit current (Iamil) in colon from sgk1-/- and sgk1+/+ mice. 
Both Vte and Iamil were significantly (p<0.05) higher in untreated sgk1-/- than in untreated 
sgk1+/+ mice under control diet. A 7 day exposure to low salt diet increased Vte and Iamil in 
both genotypes but did not abrogate the differences of Vte and Iamil between sgk1-/- and 
sgk1+/+ mice. Plasma aldosterone levels were significantly higher in sgk1-/- than in sgk1+/+ 
mice both under control conditions and under low salt diet. Treatment with 
dexamethasone (10µg/g BW) or with DOCA (1.5mg per day) significantly increased Vte 
and Iamil in sgk1+/+ mice but not in sgk1-/- mice. Under treatment  with dexamethasone or 
DOCA Vte and Iamil were similar in sgk1-/- and sgk1+/+ mice. In conclusion, lack of SGK1 
does not disrupt colonic ENaC activity and its regulation by salt depletion. 
Finally the functional significance of SGK3-dependent regulation of intestinal transport 
were studied. .Xenopus oocyte coexpression experiments revealed the capacity of SGK3 
to up-regulate a variety of transport systems including the sodium-dependent glucose 
transporter SGLT1. To this end experiments were performed in gene targeted mice 
lacking functional sgk3 (sgk3-/-) and their wild type littermates (sgk3+/+). Oral food intake 
and fecal dry weight were significantly larger in sgk3-/- than in sgk3+/+mice. Glucose-
induced current (Ig) in Ussing chamber as a measure of Na+ coupled glucose transport was 
significantly smaller in sgk3-/- than in sgk3+/+mouse jejunal segments. Fasting plasma 
glucose concentrations were significantly lower in sgk3-/- than in sgk3+/+mice. Intestinal 
electrogenic transport of phenylalanine, cysteine, glutamine and proline were not 
significantly different between sgk3-/- and sgk3+/+ mice. In conclusion, SGK3 is required 
for adequate intestinal Na+ coupled glucose transport and impaired glucose absorption 
may contribute to delayed growth and decreased plasma glucose concentrations of SGK3 
deficient mice. The hypoglycemia might lead to enhanced food intake to compensate for 
impaired intestinal absorption. 
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6 Zusammenfassung 
Die phosphoinositid-abhängige Kinase 1 (PDK1) aktiviert die SGK-Isoformen SGK1, 
SGK2 und SGK3 sowie die Isoformen der Proteinkinase B, die eine Vielzahl von 
Natrium-gekoppelten Transportern stimulieren wie z.B. den renalen und intestinalen 
glucose-Transporter SGLT1. SGK1 wird durch Mineralokortikoide hochreguliert und 
stimuliert die Aktivität des epithelialen Natrium-Kanals ENaC in verschiedenen 
Expressionssystemen. In SGK1 defizienten Mäusen (sgk1-/-) ist die amilorid-hemmbare 
transepitheliale Potentialdifferenz niedriger als in Wildtyp-Mäusen, unter Niedrigsalz-Diät 
ist die Fähigkeit zur Na-Konservierung in den sgk1-/- Mäusen eingeschränkt. Die ENaC-
Aktivität im Kolon ist ähnlich wie in der Niere mineralokortikoid-abhängig. 
Das Ziel der ersten Studie war es, den Einfluss der PDK1 am elektrogenen Glukose- und 
Aminosäurentransport im Dünndarm und im proximalen Tubulus zu untersuchen. Da 
Mäuse mit vollständigem PDK1-Verlust nicht lebensfähig sind, wurden PDK1-
hypomorphe Mäuse (pdk1hm) mit einer PDK1-Restaktivität von 10-25% untersucht. Das 
Körpergewicht der PDK1-hypomorphen Mäuse war signifikant geringer als dasjenige der 
Wildtyp-Tiere, die Futter- und Flüssigkeitsaufnahme waren jedoch ähnlich hoch. 
Ussing-Kammer-Experimente zeigten einen reduzierten elektrogenen Transport für 
Glukose sowie für die Aminosäuren Phenylalanin, Cystein, Glutamin, Prolin, Leucin und 
Tryptophan in pdk1hm -Mäusen verglichen mit pdk1wt Mäusen. Analog dazu war der 
elektrogene Transport im isolierten proximalen Tubulus für Glucose sowie für 
Phenylalanin, Glutamin und Prolin vermindert. Unter intraperitonealer Beladung mit 3 
g/kg Glucose kam es zu einer Glukosurie in pdk1hm –Mäusen, trotz ähnlich hoher 
Glukose-Spiegel wie in Wildtyp-Mäusen. Die Urinausscheidung von Prolin, Valin, 
Guanidinoacetat, Methionin, Phenylalanin, Citrullin, Glutamine/Glutamat und Tryptophan 
war in pdk1hm –Mäusen signifikant höher als in Widltyp-Mäusen. Im Western Blot von 
renalen Bürstensaum-Membranen von pdk1hm Mäusen war die Expression der Na+-
abhängigen neutralen Aminosäuren-transporter B0AT1 (SLC6A19), des Glutamat-
Transporters EAAC1/EAAT3 (SLC1A1) sowie des Transporter für kationische 
Aminosäuren und Cystin b0,+AT (SLC7A9) erniedrigt, die Expression des Na+-Prolin 
Cotransporters SIT (SLC6A20) erhöht. Zusammenfassend konnte gezeigt werden, dass 
eine Reduktion der PDK1 zu einer verminderten intestinalen Absorption sowie renalen 
Reabsorption von Glukose und Aminosäuren führte, was auf einen bisher nicht bekannten 
Regulationsweg hinweist. Der kombinierte intestinale und renale Verlust von 
VI                                                                                                              Zusammenfassung 
71 
Aminosäuren und Glukose könnte zum Minderwuchs der PDK1 hypomorphen Mäuse 
beitragen.  
In weiteren Untersuchungen wurde die transepitheliale Potentialdifferenz (Vte) und der 
amilorid-hemmbare Kurzschluss-Strom (Iamil) im Kolon von SGK1 defizienten (sgk1-/-) 
und Wildtyp-Mäusen untersucht. Sowohl Vte und Iamil waren in unbehandelten sgk1-/--
Mäusen unter Kontrolldiät signifikant höher als in sgk1+/+ Mäusen. Eine 7-tägige 
Behandlung mit einer Niedrigsalz-Diät erhöhte Vte und Iamil in beiden Genotypen, konnte 
den Unterschied in Vte und Iamil zwischen sgk1-/-- und Wildtyp-Mäusen jedoch nicht 
aufheben. Plasma-Aldosteron-Spiegel waren in sgk1-/- -Mäusen sowohl unter Kontroll-  
wie Niedrigsalz-Diät signifikant höher. Behandlung mit Dexamethason (10µg/g) oder mit 
DOCA (1.5mg/ die) erhöhte Vte und Iamil nur in Wildtyp-Mäusen, jedoch nicht in sgk1-/- 
Mäusen. Unter Behandlung mit Dexamethason oder DOCA waren sowohl Vte als auch  
Iamil in sgk1-/- und Wildtyp-Mäusen ähnlich hoch. Die Ergebnisse zeigen 
zusammengenommen, dass ein Fehlen der SGK1 nicht die Aktivität und Regulation des 
ENaCs im Kolon unterbricht. 
Zuletzt wurde die funktionelle Bedeutung der SGK3 in der Regulation des intestinalen 
Transports untersucht. Zuvor hatten Experimente im Xenopus-Expressionssystem gezeigt, 
dass die SGK3 eine Vielzahl von Transportern beeinflussen kann, u.a. den 
Glucosetransporters SGLT1. In SGK3-defizienten Mäusen (sgk3-/-) zeigte sich verglichen 
mit Wildtyp-Mäusen eine höhere Futteraufnahme und ein höheres Stuhltrockengewicht. 
Die Glukose- induzierten Ströme (Iglc) waren im Jejunum signifikant geringer in sgk3-/- - 
Mäusen als in Wildtyp-Tieren. Der Nüchtern-Blutzucker war in sgk3-/- -Mäusen 
signifikant niedriger. Der intestinale elektrogene Transport von Phenylalanin, Cystein, 
Glutamin und Prolin ware hingegen zwischen sgk3-/- und Wildtyp-Mäusen nicht 
verschieden. Daher kann gefolgert warden, dass die SGK3 für die intestinale Na+-
gekoppelte Glukoseaufnahme erforderlich ist und dass eine verminderte 
Glukoseaufnahme für die Wachstumsretardierung und die niedrigen Blutzuckerwerte 
verantwortlich sein könnte, was zu einer kompensatorischen Zunahme der Futteraufnahme 
führen könnte.  
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7 Abbreviations 
AMP   Adenosine Mono Phosphate 
ADP   Adenosine Di Phosphate 
ATP   Adenosine Tri Phosphate 
µA    Micro Amper 
µg    Micro gram 
µl   Micro liter 
µM   Micro molar 
Bw   Body weight 
BSA   Bovine serum albumin 
cAMP   Cyclic Adenosine Mono phosphate 
Camp    Cyclic Adenosine Mono phosphate 
cDNA   complementary Deoxyribonucleic Acid 
cRNA   complementary Ribonucleic Acid 
DMSO  Dimethylsulfoxide 
DNA   Deoxyribonucleic Acid 
dNTP   Deoxyribo-Nucleotidetriphosphate 
DEX   Dexamethasone 
DOCA   desoxycorticosterone acetate 
dUTP   deoxyuridine-triphosphate 
EDTA   Ethylenediamine tetraacetic acid 
ELISA   Enzyme-Linked Immunoabsorbent Assay 
ENaC    Epithelial sodium channel 
GLUT1 / 4  Glucose Transporter isoforms 1 /4 
HEPES  N-(2-Hydroxyethyl) piperazine-N-(2-ethanesulfonic acid) 
IGF1   Insulin- like growth factor 1 
Isc    Shortcircuit current  
Nedd4-2  Neuronal cell expressed developmentally down regulated 4-2 
NHE3   The Na/H-exchanger isoform 3 
NMDG  N-methyl-D-glucamine 
oC    Degree(s) Celsius (centigrade) 
PBS    Phosphate Buffered Saline 
PCR   Polymerase chain reaction 
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PDK1   Phosphoinositide-dependent kinase isoform 1 
PFA    Paraformaldehyd  
PI3K   Phosphatidyl- inositol-3-kinase 
PKA      Protein Kinase A 
PKB (Akt)   Protein Kinase B; oncogene from Akt mouse 
PKC   Protein Kinase C 
kDa   Kilo Dalton 
Ringer   Buffer Solution 
ROMK  Renal outer medullary K+ channel 
Rte   Transepithelial resistance  
SE    Standard Error  
SGKs   Serum and Glucocorticoid inducible protein Kinase isoforms 
SGLT    Sodium-glucose cotransporter 
TRIS   Tris (hydroxymethyl) aminomethane  
TUNEL   Terminal uridine deoxynucleotidyl transferase  
Vte    transepithelial potential difference  
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